document incorporate reference part portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy iii statement incorporate reference report reportitem business general segment business geographic area raw material patent trademark seasonality competition research development environment regulation available information risk factor b unresolved staff comment property legal proceeding safety disclosure executive officer registrant ii market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis result operation financial condition quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure b information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accountant fee service iv exhibit financial statement schedule summary signature exhibit index cautionary note forwardlooke statement annual report johnson johnson publicly available document contain forwardlooke statement mean safe harbor provision private security litigation reform act management representatives johnson johnson subsidiaries company time time forwardlooke statement forwardlooke statement relate strictly historical current fact reflect management assumption view plan objective projection future forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation expect operating result financial performance impact plan acquisition disposition companys strategy growth product development regulatory approval market position expenditure forwardlooke statement base current belief expectation assumption future event subject uncertainty risk change difficult predict outside company control investor realize underlying assumption prove inaccurate know unknown risk uncertainty materialize company actual result financial condition vary materially expectation projection express imply forwardlooke statement investor caution rely forwardlooke statement risk uncertainty include limited risk relate product development market success competition challenge uncertainty inherent innovation development new improved product technology company continue growth success depend include uncertainty clinical outcome obtain regulatory approval health plan coverage customer access initial continue commercial success challenge company ability obtain protect adequate patent intellectual property right new exist product technologie important market impact patent expiration typically follow introduction compete biosimilar generic result revenue market share loss increasingly aggressive frequent challenge company patent competitor seek launch compete generic biosimilar product increase receptivity court united states patent trademark office decision maker challenge potentially result loss market exclusivity rapid decline sale relevant product competition research development new improved product process technology result product process obsolescence competition reach agreement party collaboration licensing development marketing agreement product technology competition basis costeffectiveness product performance technological advance patent attain competitor allegation company product infringe patent intellectual property right party adversely affect company ability sell product question require payment money damage future royalty risk relate product liability litigation regulatory activity product efficacy safety concern base scientific evidence potentially result product withdrawal recall regulatory action food drug administration international counterpart decline sale reputational damage impact significant litigation government action adverse company include product liability claim allegation relate pharmaceutical marketing practice contracting strategy increase scrutiny health care industry government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment government business failure meet compliance obligation mcneilppc inc consent decree corporate integrity agreement johnson johnson pharmaceutical affiliate compliance agreement government government agency result significant sanction potential change applicable law regulation affect international operation include relate approval new product license patent right sale promotion health care product access reimbursement pricing health care product service environmental protection source raw material change tax law regulation increase audit scrutiny tax authority world exposure additional tax liability potentially excess reserve issuance new revise accounting standard financial accounting standard board securities exchange commission risk relate company strategic initiative health care market trend pricing pressure result trend health care cost containment include continued consolidation health care provider trend manage care shift government increasingly primary payer health care expense significant new entrant health care market seek reduce cost restrict spend pattern individual institutional governmental purchaser health care product service economic hardship budgetary constraint challenge company ability realize strategy growth include externally source innovation development collaboration strategic acquisition license marketing agreement potential heighten cost external arrangement competitive pressure potential expect strategic benefit opportunity plan complete acquisition divestiture company include integration actelion ltd realize long realize expect potential expect benefit opportunity relate past future restructuring action realize long realize expect include require consultation procedure relate restructure workforce risk relate economic condition financial market operate internationally impact inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin potential change exportimport trade law regulation policie uk country include increase trade restriction potential drug reimportation legislation impact international operation financial instability international economy sovereign risk possible imposition governmental control restrictive economic policy unstable international government legal system change global climate extreme weather natural disaster affect demand company product service cause disruption manufacture distribution network alter availability good service supply chain affect overall design integrity company product operation impact armed conflict terrorist attack part world include social economic disruption instability financial market risk relate supply chain operation difficulty delay manufacture internally supply chain lead voluntary involuntary business interruption shutdown product shortage withdrawal suspension product market potential regulatory action interruption breach company information technology system company vendor result reputational competitive operational business harm financial cost regulatory action reliance global supply chain production distribution process complex subject increase regulatory requirement adversely affect supply source pricing material company product investor carefully read risk factor describe item annual report description certain risk thing cause company actual result differ materially express forwardlooke statement investor understand possible predict identify factor consider risk describe item complete statement potential risk uncertainty company undertake publicly update forwardlooke statement time time result new information future event developmentspart item business general johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson hold company operate company conduct business virtually country world company primary focus product relate human health wellbee johnson johnson incorporate state new jersey executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activity company business segment consumer pharmaceutical medical device strategic parameter provide committee senior management group international operating company responsible strategic plan daytoday operation company subsidiary business segment limited exception manage resident country locate segment business company organize business segment consumer pharmaceutical medical device additional information require item incorporate reference narrative tabular description segment operate result item management discussion analysis result operation financial condition report note segment business geographic area note consolidated financial statement include item report consumer consumer segment include broad range product baby care oral care beauty overthecounter pharmaceutical womens health wound care market baby care include johnson line product oral care include listerine product line major brand beauty include aveeno clean clear dabao johnsons adult le petite marseillais neutrogena roc ogx product line overthecounter medicine include broad family tylenol acetaminophen product sudafe cold flu allergy product benadryl zyrtec allergy product motrin ib ibuprofen product pepcid line acid reflux product major brand women health outside north america stayfree carefree sanitary pad ob tampon brands wound care brand include bandaid brand adhesive bandage neosporin aid product line product market general public sell retail outlet distributor world pharmaceutical pharmaceutical segment focus therapeutic area immunology eg rheumatoid arthritis inflammatory bowel disease psoriasis infectious disease vaccine eg hivaids neuroscience eg mood disorder schizophrenia oncology eg prostate cancer hematologic malignancie cardiovascular metabolism eg thrombosis diabete pulmonary hypertension eg pulmonary arterial hypertension new therapeutic area establish acquisition actelion june medicine segment distribute directly retailer wholesaler hospital health care professional prescription use key product pharmaceutical segment include remicade infliximab treatment number immunemediate inflammatory disease simponi golimumab subcutaneous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adult moderate severe rheumatoid arthritis stelara ustekinumab treatment adult moderate severe plaque psoriasis active psoriatic arthritis adult moderately severely active crohn disease edurant rilpivirine prezista darunavir prezcobixrezolsta darunavircobicistat antiretroviral medicine treatment human immunodeficiency virus hiv combination antiretroviral product concerta methylphenidate hcl extendedrelease tablet cii treatment attention deficit hyperactivity disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adult invega trinzatrevicta paliperidone palmitate treatment schizophrenia patient adequately treat invega sustenna month risperdal consta risperidone longacte injection treatment schizophrenia maintenance treatment bipolar disorder adult velcade bortezomib treatment multiple myeloma use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patient previously untreate mantle cell lymphoma zytiga abiraterone acetate combination prednisone treatment metastatic castrationresistant prostate cancer imbruvica ibrutinib oral oncedaily therapy approve use treat certain bcell malignancy blood cancer waldenstrm macroglobulinemia darzalex daratumumab treatment relapsedrefractory multiple myeloma procrit eprex stimulate red blood cell production xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt lead pulmonary embolism pe patient undergo hip knee replacement surgery reduce risk stroke systemic embolism patient nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe invokana canagliflozin treatment adult type diabete invokametvokanamet canagliflozinmetformin hcl combination therapy fix dose canagliflozin metformin hydrochloride treatment adult type diabete invokamet xr canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adult type diabete opsumit macitentan monotherapy combination indicate longterm treatment pulmonary arterial hypertension pah uptravi selexipag approve oral selective ip receptor agonist target prostacyclin pathway pah medicine develop collaboration strategic partner license company maintain active lifecycle development program medical device medical device segment include broad range product orthopaedic surgery cardiovascular diabetes care eye health field product distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic include orthopaedic product general surgery biosurgical endomechanical energy product electrophysiology product treat cardiovascular disease sterilization disinfection product reduce surgical infection diabetes care product blood glucose monitor vision care product disposable contact lense ophthalmic product relate cataract laser refractive surgery geographic area business johnson johnson conduct operate company locate country include sell product virtually country world product sell international business include describe segment business consumer pharmaceutical medical device principal market product method distribution international business vary country culture product sell international business include develop subsidiary abroad investment activity country outside subject high risk comparable activity investment commercial climate influence financial instability international economy restrictive economic policy political legal system uncertaintie raw material raw material essential company business generally readily available multiple source exception temporary unavailability raw material likely material adverse effect financial result company patent company subsidiary practice obtain patent protection product process possible license significant number patent country relate product product use formulation manufacturing process aggregate believe material importance company operation business company subsidiary face patent challenge party include challenge seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product significant legal proceeding claim involve company patent intellectual property describe note legal proceedingsintellectual property note consolidated financial statement include item report sale company large product remicade infliximab account approximately company total net trade sale fiscal set patent relate specifically remicade set patent coowne janssen biotech inc whollyowne subsidiary johnson johnson nyu langone medical center nyu janssen biotech inc exclusive license nyu interest patent patent expire country outside united states united states remain patent expire september stand reject follow reexamination proceeding institute party united states patent trademark office uspto patent hold invalid federal district court district massachusetts january court appeal federal circuit affirm invalidity remain patent second set patent specifically relate remicade grant kennedy institute rheumatology europe canada australia united states janssen biotech inc license exclusive human antitnf antibodie semiexclusive nonhuman antitnf antibodie patent expire outside united states expire august united states certain patent successfully challenge invalidated review patent office world subject litigation canada company expect extension available describe patent specifically relate remicade united states biosimilar version remicade introduce additional competitor continue enter market extensive description legal matter patent relate remicade note legal proceeding intellectual property pharmaceutical remicade relate case note consolidated financial statement include item report addition compete immunology market remicade company currently market stelara ustekinumab simponi golimumab simponi aria golimumab tremfya guselkumab generation immunology product remain patent live year trademark company subsidiary practice sell product trademark obtain protection trademark available mean trademark protect registration country product market company consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line company subsidiary compete company locally globally competition exist product line regard number size compete company involve competition research internally externally source involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion research development research activity represent significant company business research development expenditure relate process discover testing develop new product upfront payment milestone improve exist product demonstrate product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity amount billion billion billion fiscal year respectively research facility locate united states belgium brazil canada china france germany israel japan netherlands switzerland united kingdom additional rd support country environment company subject variety international environmental protection measure company believe operation comply material respect applicable environmental law regulation companys compliance requirement change past year expect material effect capital expenditure cash flow earning competitive position regulation company business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation drug device cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda approval new drug device correspond increase expense product introduction similar trend evident major market outside new medical device regulatory framework new privacy regulation europe example increase regulation cost human health care continue subject study investigation regulation governmental agency legislative body world attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care generally government agency continue implement extensive requirement patient protection affordable care act aca positive negative impact healthcare industry remain uncertain provision aca potential modification repeal aca provision ultimately affect industry regulatory agency purview company operate administrative power subject action product withdrawal recall seizure product civil criminal sanction case company subsidiary deem advisable initiate product recall addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty company rely global supply chain production distribution process complex subject increase regulatory requirement face unexpected change result brexit affect source supply pricing material company product process subject lengthy regulatory approval available information company main corporate website address wwwjnjcom copy company quarterly report form q annual report current report form k file furnish securities exchange commission sec amendment foregoing provide charge shareholder submit write request secretary principal executive office company call company sec filing available company website wwwinvestorjnjcomseccfm soon reasonably practicable electronically file furnish sec sec filing available secs website wwwsecgov addition write charter audit committee compensation benefit committee nominate corporate governance committee regulatory compliance government affair committee science technology sustainability committee board director company principle corporate governance code business conduct employee code business conduct ethic member board director executive officer corporate governance material available wwwinvestorjnjcomgovcfm company website provide charge shareholder submit write request provide information company website deem report incorporate filing company make sec item risk factor company face number uncertainty risk difficult predict outside company control addition information report company filing sec investor consider carefully factor set forth investor aware possible predict identify factor follow mean complete discussion potential risk uncertainty know unknown risk uncertainty materialize company business result operation financial condition adversely affect potentially material way company large product remicade infliximab experience biosimilar competition result reduction sale remicade company experience significant challenge patent cover large product remicade infliximab account approximately company total net trade sale fiscal continue assert certain patent relate product united states biosimilar version remicade introduce additional competitor continue enter market sale infliximab biosimilar market result continue reduction sale remicade global sale company pharmaceutical medical device segment negatively impact healthcare reform increase pricing pressure sale companys pharmaceutical medical device product significantly affect reimbursement thirdparty payer government healthcare program private insurance plan manage care organization effort contain healthcare cost payer put downward pressure price product reimburse united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary continued consolidation health care provider result pricing pressure addition increase political scrutiny result additional pricing pressure outside united states numerous major market include eu japan pervasive government involvement funding healthcare regard directly indirectly impose price control limit access reimbursement company product reduce value intellectual property protection company subject significant legal proceeding result significant expense fine reputational damage ordinary course business johnson johnson subsidiary subject numerous claim lawsuit involve issue patent dispute product liability claim product sale marketing pricing practice violate antitrust unfair trade practice andor consumer protection law significant proceeding describe note legal proceeding note consolidated financial statement include item report company believe substantial defense matter feasible predict ultimate outcome litigation company future require pay significant amount result settlement judgment matter potentially excess accrual resolution increase accrual matter report period material adverse effect company result operation cash flow period furthermore result cost availability factor effective november company cease purchase thirdparty product liability insurance product reliability safety effectiveness concern significant negative impact sale result operation lead litigation cause reputational damage concern product safety raise internally litigant regulator consumer advocate base scientific evidence result safety alert product recall governmental investigation regulatory action fda counterpart country private claim lawsuit payment fine settlement decline sale reputational damage circumstance result damage brand image brand equity consumer trust company product product recall past future prompt government investigation inspection shutdown manufacture facility continue product shortage relate sale decline significant remediation cost reputational damage possible civil penalty criminal prosecution change tax law exposure additional tax liability negatively impact company operating result change tax law regulation negatively impact company effective tax rate result operation december enact tax cut job act tcja result revaluation company relate defer tax asset liability impact company consolidate statement earning tcja introduce significant change corporate income tax law meaningful impact company provision income taxis account income tax effect tcja require significant judgment interpret provision time enactment complexity involve apply provision tcja company reasonable estimate effect record provisional amount financial statement fiscal year provisional amount base company initial analysis tcja january anticipate guidance treasury implement tcja potential additional guidance securities exchange commission financial accounting standard board relate tcja result adjustment estimate materially affect company financial position result operation effective tax rate period adjustment government switzerland currently consider tax reform legislation material impact company effective tax rate enact law company conduct business file tax return numerous country address tax audits dispute tax authority connection organization economic cooperation development base erosion profit shift bep project company require disclose information tax authority operation world lead great audit scrutiny profit earn country company regularly assess likely outcome tax audits dispute determine appropriateness tax reserve tax authority position tax treatment contrary company expectation result tax liability excess reserve company able successfully secure defend intellectual property right essential company business company own license significant number patent proprietary right determine patent office court lawmaker country relate product manufacturing process right essential company business materially important company result operation public policy outside increasingly unfavorable intellectual property right company certain obtain adequate patent protection new product technologie important market protection grant long originally anticipate competitor routinely challenge validity extent company own licensed patent proprietary right litigation interference opposition proceeding proceeding absorb resource protract unpredictable addition challenge company product infringe patent party result need pay past damage future royalty adversely affect competitive position sale product question company face increase patent challenge party seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product united states manufacturers generic version innovative human pharmaceutical product challenge validity claim noninfringement innovator product abbreviate new drug application anda process fda biologics price competition innovation act bpcia enact create new regulatory pathway approval fda biosimilar alternative innovatordevelope biological product create mechanism biosimilar applicant challenge patent innovator biologics inter part review ipr process uspto created america invents act competitor challenge patent hold company subsidiary example key patent zytiga currently subject patent litigation uspto issue decision invalidate patent relate ipr action event company successful defend patent challenge atrisk launch despite pende patent infringement litigation generic biosimilar firm product company lose major portion revenue reference product short period time current legal proceeding involve company patent intellectual property right describe note legal proceedingsintellectual property note consolidated financial statement include item report company business operate highly competitive product market competitive pressure adversely affect company earning company face substantial competition operate segment geographic market company business compete company size basis costeffectiveness technological innovation intellectual property right product performance real perceive product advantage price availability rate reimbursement company compete market participant secure right acquisition collaboration license agreement party competition right product candidate technology result significant investment acquisition cost onerous agreement term company competitor development effective costly product andor ability secure patent intellectual property right successfully market product ahead company negatively impact sale company exist product ability bring new product market despite significant prior investment relate product development company pharmaceutical business loss patent exclusivity product follow substantial reduction sale competitor gain regulatory approval generic compete product enter market similar competition trigger loss exclusivity biological product company medical device business technological innovation product quality reputation customer service especially important competitiveness development company new improved product process technology threaten company product technology desirable economical obsolete company consumer business face intense competition brand product retailer privatelabel brand company fail sufficiently differentiate market brand consumer product adversely affect revenue profitability product significant challenge delay company innovation development new product technology indication adverse impact company longterm success company continue growth success depend ability innovate develop new differentiate product service address evolve health care need patient provider consumer development successful product technology necessary offset revenue loss company exist product lose market share factor competition loss patent exclusivity new product introduce past year account approximately sale company certain able develop license acquire company product technology particular product candidate grant regulatory approval approve product commercially successful company pursue product development internal research development collaboration acquisition joint venture license arrangement party context develop new product particularly pharmaceutical biotechnology product medical device require significant investment resource year biopharmaceutical research development program result commercially viable product process depend factor include ability discern patient health care provider future need develop promise new compound strategy technology achieve successful clinical trial result secure effective intellectual property protection obtain regulatory approval timely basis reach market successfully differentiate company product compete product approach treatment new product enhancement exist product accept quickly significantly marketplace product price competition change customer preference healthcare purchasing pattern resistance healthcare provider uncertainty thirdparty reimbursement follow initial regulatory approval success product adversely impact safety efficacy finding large real world patient population market entry competitive product company face increase regulatory scrutiny impose significant compliance cost expose company government investigation legal action penalty like company healthcare industry company subject extensive regulation investigation legal action national state local government agency united states country operate regulatory issue compliance good manufacturing practice cgmp comparable quality regulation foreign country manufacturer drug device consumer product lead fine penalty product recall product shortage interruption production delay new product approval litigation addition marketing pricing sale company product subject regulation investigation legal action include federal food drug cosmetic act medicaid rebate program federal state false claim act state unfair trade practice act consumer protection law increase scrutiny health care industry business practice recent year government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment participation government healthcare program debarment material adverse effect company business result operation significant current investigation litigation bring government agency describe note legal proceedingsgovernment proceeding note consolidated financial statement include item report company face variety risk associate conduct business internationally company extensive operation business activity outside accompany certain financial economic political risk include list foreign currency exchange fiscal approximately company sale occur outside approximately europe western hemisphere exclude asiapacific africa region change nonus currency relative dollar impact company revenue expense company use financial instrument mitigate impact fluctuation currency exchange rate cash flow unhedged exposure continue subject currency fluctuation addition weaken strengthen dollar result significant favorable unfavorable translation effect operating result company nonus business activity translate dollar inflation currency devaluation risk company face challenge maintain profitability operation economy experience high inflation rate company account operation venezuela highly inflationary prior threeyear cumulative inflation rate surpass company strive maintain profit margin area cost reduction program productivity improvement periodic price increase experience operating loss result continued inflation addition impact currency devaluation country experience high inflation rate significant currency exchange fluctuation negatively impact company operate result illegal importation pharmaceutical product illegal importation pharmaceutical product country government price control market dynamic result low price adversely affect company sale profitability country company operate exception limited quantity prescription drug personal use foreign import pharmaceutical product illegal current law volume illegal import continue rise ability patient customer obtain lowerprice import grow significantly antibribery regulation company subject federal foreign law govern international business practice respect payment government official law include foreign corrupt practice act fcpa prohibit publicly trade company promise offering give value foreign official corrupt intent influence foreign official purpose help company obtain retain business gain improper advantage company business heavily regulate involve significant interaction foreign official country outside health care provider prescribe human pharmaceutical employ government purchaser human pharmaceutical government entity company interaction prescriber purchaser subject regulation fcpa addition application enforcement fcpa jurisdiction company operate law regulation include uk bribery act aim prevent penalize corrupt anticompetitive behavior enforcement activity law subject company additional administrative legal proceeding action include claim civil penalty criminal sanction administrative remedy include exclusion health care program legal social political risk risk inherent conduct business globally include protective economic policy take government trade protection measure importexport licensing requirement compliance local regulation law include country regulatory requirement restrict company ability manufacture sell product relevant market diminish protection intellectual property contractual right certain jurisdiction potential nationalization expropriation company foreign asset disruption market war armed conflict terrorism social upheaval pandemic interruption delay manufacture operation adversely affect company business sale reputation company manufacture product require timely delivery sufficient amount complex highquality component material company subsidiary operate manufacturing facility source hundred supplier world company past future face unanticipated interruption delay manufacture internal external supply chain manufacturing disruption occur reason include regulatory action production quality deviation safety issue labor dispute sitespecific incident fire natural disaster hurricane severe weather event raw material shortage political unrest terrorist attack delay difficulty manufacturing result product shortage decline sale reputational impact significant remediation relate cost associate address shortage information security incident include cybersecurity breach negative impact company business reputation meet business objective company rely internal information technology system network party vendor process store sensitive datum include confidential research business plan financial information intellectual property personal datum subject legal protection extensive information security cybersecurity threat affect company globally pose risk security availability system network confidentiality integrity availability company sensitive datum company continually assess threat make investment increase internal protection detection response capability ensure company party provider require capability control address risk date company experience material impact business operation result information cybersecurity attack frequently change attack technique increase volume sophistication attack potential company adversely impact impact result reputational competitive operational business harm financial cost regulatory action item b unresolved staff comment applicable item property company subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment company business approximately follow square foot segment thousand consumer pharmaceutical medical device worldwide total united states seven facility consumer segment pharmaceutical segment medical device segment outside united states facility consumer segment pharmaceutical segment medical device segment location manufacture facility major geographic area world follow square foot geographic area number facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss company maintain numerous office warehouse facility world research facility discuss item report business research development company subsidiary generally seek manufacture facility principally nonus location lease office warehouse facility lease company engage contract manufacturer company commit maintain property good operating condition mcneilppc inc johnson johnson consumer inc mcneilppc continue operate consent decree sign fda govern certain mcneil consumer healthcare manufacturing operation require mcneilppc remediate facility operate lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree follow fda inspection mcneilppc receive notification fda manufacture facility conformity applicable law regulation commercial production restart consent decree receiving notice fda compliance applicable law regulation facility subject fiveyear audit period thirdparty cgmp expert thirdparty expert continue reassess site time information lease obligation note rental expense lease commitment note consolidated financial statement include item report segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement include item report item legal proceeding information call item incorporate reference information set forth note legal proceeding note consolidated financial statement include item report addition johnson johnson subsidiaries time time party government investigation inspection proceeding relate environmental matter include compliance applicable environmental law item safety disclosure applicable executive officer registrant list executive officer company family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include information alex gorsky executive officer incorporate reference material caption item election director proxy statement age position dominic j caruso member executive committee executive vice president chief financial officer joaquin duato member executive committee executive vice president worldwide chairman pharmaceuticalsb peter fasolo member executive committee executive vice president chief human resource officerc alex gorsky chairman board directors chairman executive committee chief executive officer jorge mesquita member executive committee executive vice president worldwide chairman consumerd sandra e peterson member executive committee executive vice president group worldwide chairmane paulus stoffels member executive committee executive vice president chief scientific officerf michael h ullmann member executive committee executive vice president general counselg mr j caruso join company company acquire centocor inc senior vice president finance mr caruso name vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance company medical device diagnostic group mr caruso name vice president company group finance organization mr caruso member executive committee vice president finance chief financial officer april name executive vice president chief financial officer mr caruso responsibility financial investor relation activity company procurement organization b mr j duato join company janssenfarmaceutica sa spain manage director janssencilag spa italy lead ortho biotech europe relocate united states serve vice president president ortho biotech inc name company group chairman orthoclinical diagnostic company group chairman pharmaceuticals oversaw pharmaceutical product launch major therapeutic franchise canada united states latin america name worldwide chairman pharmaceutical responsible global commercial business janssen pharmaceutical company include functional support research development organization april mr duato member executive committee name executive vice president worldwide chairman pharmaceuticals c dr p fasolo join company vice president worldwide human resource cordis corporation subsidiary company subsequently name vice president global talent management company leave johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo return company vice president global human resource member executive committee april name executive vice president chief human resource officer mr fasolo responsibility global talent recruiting diversity compensation benefit employee relation aspect human resource company mr j mesquita join company worldwide chairman consumer prior join company serve marketing leadership capacity latin america include role oral care beauty procter gamble company april mr mesquita member executive committee name executive vice president worldwide chairman consumer e ms e peterson join company group worldwide chairman member executive committee prior join company ms peterson chairman chief executive officer bayer cropscience ag germany previously serve president chief executive officer bayer medical care president bayer healthcare ag diabetes care division join bayer ms peterson hold number leadership role medco health solution previously know merckmedco april ms peterson name executive vice president group worldwide chairman johnson johnson ms peterson responsible company consumerface business include consumer family company consumer medical device business company medical device business supply chain quality information technology design enterprise f dr p stoffels join company acquisition tibotec virco nv chief executive officer virco nv chairman tibotec nv appoint company group chairman global virology assume role company group chairman pharmaceutical responsibility worldwide research development central nervous system internal medicine franchise dr stoffels appoint global head research development pharmaceutical worldwide chairman pharmaceutical responsibility company therapeutic pipeline global research development strategic business development dr stoffel appoint chief scientific officer responsibility enterprisewide innovation product safety member executive committee april dr stoffel name executive vice president chief scientific officer responsible company innovation pipeline pharmaceutical medical device consumer segment steer company global public health strategy g mr h ullmann join company corporate attorney law department appoint corporate secretary serve role time hold management position law department name general counsel medical device diagnostic appoint vice president general counsel member executive committee april mr ullmann name executive vice president general counsel mr ullmann worldwide responsibility legal government affair policy global security aviation health care compliance privacy ii item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference follow section report item management discussion analysis result operation financial condition liquidity capital resource dividend information common stock market price note common stock stock option plan stock compensation agreement note consolidated financial statement include item item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information issuer purchase equity securities october company announce board director approve share repurchase program authorize company purchase billion company common stock share repurchase place open market time time base market condition july billion repurchase program program complete follow table provide information respect common stock purchase company fiscal fourth quarter common stock purchase open market systematic plan meet need company compensation program repurchase include stockforstock option exercise settle fiscal fourth quarter total number maximum number share unit approximate dollar value purchase share unit total number publicly purchase share avg price announce plan plan period purchase pay share program programs october october october november november december total fiscal fourth quarter company repurchase aggregate share johnson johnson common stock openmarket transaction systematic plan meet need company compensation program july share repurchase program complete aggregate share purchase total billion inception repurchase program announce october item select financial datum summary operation statistical data dollar million share amount sale customer sale customer international total sale cost product sell sell marketing administrative expense research development expense inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income net earning add net loss attributable noncontrolle interest net earning attributable johnson johnson percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase decrease previous year sale customer dilute net earning share supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand attributable johnson johnson item management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device consumer segment include broad range product baby care oral care beauty overthecounter pharmaceutical womens health wound care market product market general public sell retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler hospital health care professional prescription use medical device segment include broad range product orthopaedic surgery cardiovascular diabetes care vision care field distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device business segment product line company compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion management objectives credo foundation company purpose blend heart science ingenuity profoundly change trajectory health humanity company commit bring breadth depth ensure health people today future generation unite common ambition company poise fulfill purpose successfully meet demand rapidly evolve market compete company broadly base human healthcare commit create value develop accessible high quality innovative product service new product introduce past year account approximately sale billion invest research development billion spend acquisition reflect management commitment create lifeenhancing innovation create value partnership profoundly change trajectory health humanity critical driver company success diverse employee work operate company locate country employee empower inspire lead company credo purpose guide allow employee use company reach size advance company purpose lead agility urgency leverage extensive resource enterprise enable company innovate execute excellence ensure company remain focused address unmet need society day invest endure impact ultimately deliver value patient consumer healthcare professional employee communitie shareholder result operation analysis consolidate sale worldwide sale increase billion compare increase decrease sale change consist follow sale increasedecrease volume price currency total net impact acquisition divestiture worldwide sale growth positive impact acquisition divestiture negative impact worldwide sale growth competitive product company hepatitis c product olysiosovriad simeprevir incivo telaprevir negative impact worldwide sale growth operation venezuela negatively impact worldwide sale growth introduction competitive product company hepatitis c product olysiosovriad simeprevir incivo telaprevir negative impact worldwide sale growth impact acquisition divestiture worldwide sale growth negative sale company billion billion billion represent increase sale international company billion billion billion represent increase decrease fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively sale company europe achieve growth compare prior year include operational growth positive currency impact sale company western hemisphere exclude achieve growth compare prior year include operational growth positive currency impact sale company asiapacific africa region achieve growth compare prior year include operational growth partially offset negative currency impact sale growth percentage compare prior year negatively impact approximately additional shipping day note consolidated financial statement annual closing date detail additional week add day sale add week worth operating cost net earning impact negligible company wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue analysis sale business segment consumer segment consumer segment sale billion increase include operational growth positive currency impact consumer segment sale billion increase international sale billion increase include operational growth positive currency impact acquisition divestiture net positive impact operational sale growth worldwide consumer segment major consumer franchise sale change dollar million vs vs beauty otc baby care oral care womens health wound careother total consumer sale beauty franchise sale billion increase compare prior year growth primarily drive inclusion sale recent acquisition vogue international llc dr ci labo sale growth neutrogena product overthecounter otc franchise sale billion increase compare prior year growth primarily drive analgesic product upper respiratory product outside sale recent acquisition rhinocort antismoke aids baby care franchise sale billion decrease compare prior year primarily competitive pressure oral care franchise sale billion decrease compare prior year primarily drive category decline competitive pressure partially offset new product launch outside womens health franchise sale billion decrease compare prior year primarily category decline emea share loss brazil wind careother franchise sale billion decrease compare prior year primarily private label competitive pressure partially offset bandaid new product launch outside consumer segment sale billion decrease include operational growth offset negative currency impact consumer segment sale billion increase international sale billion decrease include operational growth offset negative currency impact impact acquisition divestiture consumer segment operational sale growth negative consumer segment operational sale growth negatively impact operation venezuela negatively impact additional shipping day pharmaceutical segment pharmaceutical segment sale billion increase include operational growth positive currency impact sale billion increase international sale billion increase include operational growth positive currency impact acquisition divestiture net positive impact operational sale growth worldwide pharmaceutical segment adjustment previous reserve estimate compare prior year negatively impact report pharmaceutical segment operational growth approximately primarily immunology cardiovascularmetabolismother therapeutic area major pharmaceutical therapeutic area sale change dollar million vs vs total immunology remicade simponisimponi aria stelara immunology total infectious disease edurantrilpivirine prezista prezcobixrezolstasymtuza infectious disease total neuroscience concertamethylphenidate invega sustennaxepliontrinzatrevicta risperdal consta neuroscience total oncology darzalex imbruvica velcade zytiga oncology pulmonary hypertension opsumit tracleer uptravi cardiovascular metabolism xarelto invokana invokamet procriteprex total pharmaceutical sale prior year amount reclassify conform current year presentation percentage great meaningful product acquire actelion june immunology product achieve sale billion represent increase compare prior year growth drive strong uptake stelara ustekinumab launch tremfya guselkumab sales growth simponisimponi aria golimumab outside low sale remicade infliximab increase discountsrebate biosimilar competition patent remicade infliximab certain country europe expire february biosimilar version remicade introduce certain market outside united states result reduction sale remicade market additional biosimilar competition likely result reduction remicade sale market outside united states united states biosimilar version remicade introduce additional competitor continue enter market continue infliximab biosimilar competition market result reduction sale remicade company continue assert remicade relate patent right note consolidated financial statement description legal matter remicade patent infectious disease product sale billion decline low sale olysio simeprevir vaccine prezista darunavircobicistat partially offset sale growth edurantrilpivirine prezcobixrezolsta launch symtuza neuroscience product sale billion decrease low sale risperdal consta risperidone concertamethylphenidate impact divestiture partially offset strong sale invega sustennaxeplion trinzatrevictapaliperidone palmitate longacte injectable oncology product achieve sale billion represent increase compare prior year contributor growth oncology product strong sale darzalex daratumumab imbruvica ibrutinib drive market share market growth sale zytiga abiraterone acetate drive market growth generic company challenge remain patent zytiga uspto united states district court district new jersey company appeal decision uspto invalidate patent party await decision motion summary judgment noninfringement file generic company event ruling unfavorable company generic launch expect follow launch generic version zytiga follow fda approval result reduction sale reduction occur short period time company report sale billion zytiga note consolidated financial statement description legal matter zytiga pulmonary hypertension new therapeutic area establish acquisition actelion ltd june note consolidated financial statement additional detail acquisition cardiovascularmetabolismother product sale billion decline compare prior year attributable low sale invokanainvokamet canagliflozin primarily increase price discount market share decline drive competitive pressure partially offset sale growth xareltorivaroxaban increase market growth market share sale nonpah pulmonary arterial hypertension product actelion acquisition company advanced pipeline regulatory submission approval new drug additional indication exist drug follow product chemical indication approv eu approv file eu file apalutamide oral androgen receptor inhibitor man nonmetastatic castration resistant prostate cancer darzalex daratumumab combination lenalidomide dexamethasone bortezomib dexamethasone treatment patient multiple myeloma receive prior therapy combination pomalidomide dexamethasone bortezomib dexamethasone treatment patient multiple myeloma receive prior therapy frontline multiple myeloma transplant ineligible patient combination bortezomib melphalan prednisone treatment adult patient chronic graftversushostdisease failure imbruvica ibrutinib line systemic therapy marginal zone lymphoma invokana canagliflozin reduce risk death type diabete establish risk cardiovascular disease canvascanvasr juluca rilpivirine singletablet twodrug regimen dolutegravir rilpivirine dolutegravir maintenance treatment hiv infection simponi aria golimumab treatment adult live active psoriatic arthritis treatment adult live active ankylose spondylitis stelara ustekinumab treatment adolescent year age moderate severe plaque psoriasis symtuza darunavircobicistatsingle tablet regimen hiv treatment nave patient treatment emtricitabinetenofovir experience patient alafenamide tremfya guselkumab treatment adult live moderate severe plaque psoriasis xarelto rivaroxaban mg oncedaily dose reduce continue risk recurrent venous thromboembolism complete month initial anticoagulation therapy new vascular indication reduce risk major cardiovascular event reduce risk acute limb ischemia patient pad zytiga abiraterone acetate prostate cancer newly diagnose hormone nave metastatic pharmaceutical segment sale billion increase include operational growth partially offset negative currency impact sale billion increase international sale billion increase include operational growth partially offset negative currency impact acquisition divestiture competitive product company hepatitis c product olysiosovriad simeprevir incivo telaprevir negative impact operational growth pharmaceutical segment pharmaceutical segment operational growth negatively impact additional shipping day pharmaceutical segment operational growth compare prior year impact adjustment previous reserve estimate period include approximately billion adjustment medical device segment medical device segment sale billion increase include operational increase positive currency impact sale billion increase compare prior year international sale billion increase compare prior year operational increase positive currency impact acquisition divestiture net positive impact worldwide operational sale growth medical device segment compare major medical device franchise sale change dollar million vs vs surgery advanced general specialty orthopaedic hip knee trauma spine vision care contact lensesother surgical cardiovascular diabetes care diagnostic total medical device sale product acquire abbott medical optics amo february june company divest orthoclinical diagnostic business diagnostic franchise surgery franchise sale billion increase growth advanced surgery primarily drive endocutter energy include acquisition megadyne medical products inc biosurgery product growth general surgery primarily drive suture sale acquisition torax medical inc sale decline specialty surgery primarily low sale aesthetic advanced sterilization sterilme product orthopaedic franchise sale billion decrease decline spine primarily codman neurosurgery divestiture share loss spine pricing competitive pressure partially offset sale growth trauma sport medicine product hips vision care franchise achieve sale billion increase growth drive sale acquisition amo majority amo sale surgical category new product launch contact lense category cardiovascular franchise sale billion increase strong growth electrophysiology business drive market growth continue uptake thermocool smarttouch contact force sense catheter diabetes care franchise sale billion decrease decline primarily price decline competitive pressure additionally fourth quarter company announce decision exit animas insulin pump business animas select medtronic plc facilitate seamless transition patient caregiver healthcare provider company continue evaluate potential strategic option lifescan inc determine good opportunity drive future growth maximize shareholder value medical device segment sale billion decrease include operational increase negative currency impact sale billion increase compare prior year international sale billion decrease compare prior year operational increase negative currency impact acquisition divestiture negative impact worldwide operational growth medical device segment compare medical device segment operational growth negatively impact additional shipping day analysis consolidate earning provision taxis income consolidated earning provision taxis income decrease billion compare billion decrease decrease primarily attributable high amortization expense charge relate recent acquisition high selling marketing administrative cost investment new product launch high research development cost general portfolio progression collaboration consolidated earning provision taxis income increase billion compare billion increase increase primarily attributable high sale volume favorable mix business low selling marketing administrative cost partially offset high net litigation expense billion high restructure charge billion compare additionally fiscal year include high gain sale assetsbusinesse compare percent sale consolidated earning provision taxis income versus cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow sale cost product sell percent point increasedecrease prior year sell marketing administrative expense percent point increasedecrease prior year cost product sell percent sale increase compare period year ago unfavorable increase primarily drive billion high amortization expense charge inventory stepup relate recent acquisition primarily actelion intangible asset amortization expense billion include cost product sell compare billion increase percent sale sell marketing administrative expense compare prior year primarily investment new product launch partially offset favorable mix cost product sell percent sale decrease compare period year ago favorable mix business cost improvement program partially offset unfavorable impact transactional currency intangible asset amortization expense billion include cost product sell decrease percent sale sell marketing administrative expense compare prior year primarily cost management segment favorable mix research development expense research development expense segment business follow dollar million sale sale sale consumer pharmaceutical medical device total research development expense percent increasedecrease prior year percent segment sale research development activity represent significant company business expenditure relate process discover testing develop new product upfront payment milestone improve exist product ensure product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity increase compare increase percent sale primarily pharmaceutical segment general portfolio progression collaborative agreement enter idorsia ltd legend biotech worldwide cost research development activity increase compare decrease percent sale decrease percent sale attributable high overall sale pharmaceutical segment increase dollar spend pharmaceutical segment investment spending advance pipeline inprocess research development iprd company record iprd charge billion primarily discontinuation certain development project relate novira acquire product development cancel safety concern company record iprd charge million discontinuation development program relate crucell company record iprd charge billion primarily discontinuation certain development project relate covagen income expense net income expense net account company record gain loss relate sale writedown certain investment equity security hold johnson johnson innovation jjdc inc jjdc gain loss divestiture transactional currency gain loss acquisitionrelate cost litigation accrual settlement royalty income change income expense net fiscal year favorable change billion high gain billion sale assetsbusinesse primarily codman neurosurgery compeed divestiture gain billion relate monetization future royalty receivables high gain billion relate sale certain investment equity security compare prior year partially offset high litigation expense billion billion acquisition cost relate actelion amo asset impairment charge billion primarily relate insulin pump business high restructuring relate charge billion compare fiscal year change income expense net fiscal year unfavorable change billion compare prior year primarily high gain sale assetsbusinesse fiscal year compare fiscal year include gain billion divestiture control substance raw material api business certain anesthetic product europe certain nonstrategic consumer brand versus gain billion record primarily divestiture cordis business divestiture nucynta splenda brand additionally fiscal year include high litigation expense billion compare partially offset billion intangible asset writedown relate acclarent include fiscal year interest income expense interest income increase slightly compare high average interest rate partially offset low cash cash equivalent marketable security balance period cash cash equivalent marketable security total billion end average billion compare billion average cash balance decrease balance cash cash equivalent marketable security use cash general corporate purpose include acquisition primarily actelion acquisition billion net cash acquire interest expense high compare average debt balance billion versus billion total debt balance end billion compare billion end high debt balance approximately billion primarily increase borrowing company increase borrowing february november capitalize favorable term capital market proceed borrowing general corporate purpose include completion stock repurchase program interest income increase billion compare high average balance cash cash equivalent marketable security high interest rate cash cash equivalent marketable security total billion end average billion compare billion average cash balance interest expense higher compare average debt balance billion versus billion total debt balance end billion compare billion end high debt balance approximately billion primarily increase borrowing february company increase borrowing capitalize favorable term capital market proceed borrowing general corporate purpose primarily stock repurchase program income tax segment income tax segment business follow income tax segment sale percent segment sale dollar million consumer pharmaceutical medical device total expense allocate segment earning provision taxis income note consolidated financial statement detail amount allocate segment include interest income expense general corporate income expense increase primarily high interest expense billion high debt balance consumer segment consumer segment income tax percent sale versus increase income tax percent sale compare attributable high gain divestiture primarily divestiture compeed partially offset high selling marketing administrative expense compare prior year increase advertising promotional spending slightly high amortization expense relate acquisition additionally fiscal year negatively impact operation venezuela consumer segment income tax percent sale versus primarily drive favorable selling marketing administrative expense cost management high gross profit margin cost improvement project favorable mix partially offset high gain relate divestiture primarily divestiture splenda brand additionally operation venezuela negatively impact consumer segment income tax compare pharmaceutical segment pharmaceutical segment income tax percent sale versus decrease income tax percent sale primarily billion high amortization expense cost relate actelion acquisition high research development expense high iprd charge billion relate novira low gain divestiture compare prior year additionally fiscal year include positive adjustment billion previous reserve estimate partially offset gain billion relate monetization future royalty receivables high gain billion relate sale certain investment equity security favorable product mix pharmaceutical segment income tax percent sale versus increase income tax primarily strong sale volume growth favorable selling marketing administrative expense cost management additionally fiscal year high gain billion relate divestiture partially offset high iprd charge billion compare fiscal year include gain divestiture control substance raw material api business certain anesthetic product europe versus gain record divestiture nucynta medical device segment medical device segment income tax percent sale versus decrease income tax percent sale primarily billion high amortization expense acquisition cost relate amo billion high litigation asset impairment charge billion primarily relate insulin pump business billion high restructure investment new product launch compare fiscal year partially offset billion high gain relate divestiture primarily divestiture codman neurosurgery medical device segment income tax percent sale versus decrease income tax percent sale primarily low gain billion relate divestiture high litigation expense billion high restructure charge billion compare partially offset intangible asset writedown billion related acclarent favorable selling marketing administrative expense restructure quarter company announce restructuring action medical device segment restructuring action expect result annualize pretax cost saving million billion majority expect realize end approximately million saving realize saving provide company add flexibility resource fund investment new growth opportunity innovative solution customer patient company estimate connection plan record pretax restructure relate charge approximately billion billion company record pretax charge million million include cost product sell million include income expense company record pretax charge million million include cost product sell million include income expense company record pretax charge million million include cost product sell restructure relate charge billion record restructure announce note consolidated financial statement additional detail relate restructuring provision taxis income worldwide effective income tax rate effective tax rate increase compare primarily drive enactment tax cut job act tcja united states december enactment tcja result provisional tax charge fourth quarter approximately billion approximately percentage point increase effective tax rate note consolidated financial statement additional detail relate tcja remainder increase tax rate relate remeasurement company defer tax asset belgium result change belgian statutory corporate tax rate enact december offset tax benefit closure company animas insulin pump business government switzerland currently consider tax reform legislation material impact company effective tax rate enact law decrease effective tax rate compare primarily attributable company adopt new accounting standard report additional tax benefit sharebase compensation vest exercise fiscal year remainder change effective tax rate primarily relate low earning taxis united states settlement uncertain tax position versus decrease effective tax rate compare primarily attributable increase taxable income low tax jurisdiction relative high tax jurisdiction tax benefit result restructure international affiliate liquidity capital resource liquidity cash flow cash cash equivalent billion end compare billion end primary source use cash contribute billion decrease approximately billion cash generate operating activity billion effect exchange rate change cash cash equivalent offset billion net cash investing activity billion net cash financing activity addition company billion marketable security end billion end note consolidated financial statement additional detail cash cash equivalent marketable security cash flow operation billion result billion net earning billion noncash expense adjustment depreciation amortization stockbase compensation asset writedown defer tax provision reduce billion net gain sale assetsbusinesse billion relate increase account receivable increase current noncurrent asset additional source operate cash flow billion result increase account payable accrue liability decrease inventory increase current noncurrent liability increase accrue liability noncurrent liability primarily tax legislation tcja tax billion payable year additionally foreign taxis billion net record defer tax provision investing activity use billion acquisition net cash acquire billion primarily acquisition actelion amo approximately billion billion respectively addition property plant equipment billion partially offset proceed net sale investment primarily marketable security billion billion proceed disposal assetsbusinesse primarily divestiture codman neurosurgery compeed financing activity use billion primarily dividend shareholder billion billion repurchase common stock billion financing financing activity include source billion net proceed short longterm debt billion proceed stock option exercisedemployee withholding tax stock awards net october company announce board director approve share repurchase program authorize company purchase billion company share common stock july billion repurchase program program complete share acquire available general corporate purpose december company note payable longterm debt excess cash cash equivalent marketable security company continue access liquidity commercial paper market additionally result tcja company access cash outside significantly reduce cost company anticipate operate cash flow ability raise fund external source borrowing capacity exist committed credit facility access commercial paper market continue provide sufficient resource fund operating need month company monitor global capital market ongoing basis time time raise capital market condition favorable company file new shelf registration february enable issue debt security timely basis fiscal fourth quarter company issue bond total billion general corporate purpose include completion stock repurchase program additional detail borrowing note consolidated financial statement finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency transaction primarily relate product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future anticipate earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future anticipate cash flow company enter financial instrument trade speculative purpose company policy enter contract party investment grade credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote company invest fix rate float rate interest earn security carry degree interest rate risk fair market value fix rate security adversely impact rise interest rate float rate security produce income predict interest rate fall basis point change spread company interest rate sensitive investment increase decrease unrealized value cash equivalent current marketable security approximately million company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material total borrowing end billion billion respectively increase borrowing result finance company share repurchase program general corporate purpose net debt cash current marketable security net debt billion compare net cash billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend decrease summary borrowing find note consolidated financial statement contractual obligation commitment company contractual obligation primarily recently enact tax legislation lease debt unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity december note consolidated financial statement detail tax legislation interest unfunded dollar millions tcja debt obligation debt obligation retirement plan operating lease total total tax matter note consolidated financial statement retirement plan postemployment medical benefit information note consolidated financial statement table include activity relate business combination dividend company increase dividend th consecutive year cash dividend pay share compare dividend share share dividend distribute follow quarter second quarter quarter fourth quarter total january board director declare regular quarterly cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept gaap preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal self insurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock base awards revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record note consolidated financial statement accounting standard update relate revenue adopt product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate include medicaid rebate provision estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual net trade sale fiscal reporting year promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product year present service revenue approximately total revenue include sale customer arrangement evaluate determine appropriate amount defer record reduction revenue addition company enter collaboration arrangement contain multiple revenue generating activity amount collaborative partner arrangement recognize activity perform deliver base relative selling price upfront fee receive arrangement defer recognize performance period note consolidated financial statement additional disclosure collaboration reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual filing material financial statement impact table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business fiscal year end december january consumer segment balance balance dollar million begin period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset pharmaceutical segment balance balance dollar million begin period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset include adjustment medical device segment balance balance dollar million begin period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position fourth quarter united states enact tcja include provision tax previously undistributed earning foreign jurisdiction company provisionally book billion charge undistribute earning additionally company provisionally record billion defer tax liability foreign local withholding taxis offset billion defer tax asset foreign tax credit repatriation substantially undistributed foreign earning company currently evaluate remain undistributed foreign earning provide defer taxis foreign local withholding tax earning consider indefinitely reinveste unrecorde defer taxis expect material note consolidated financial statement information income taxis legal self insurance contingency company record accrual contingency include legal proceeding product liability claim arise normal course business accrual base management judgment probability loss applicable actuarially determined estimate company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue note consolidated financial statement information product liability legal proceeding longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset mortality rate expect salary increase health care cost trend rate attrition rate note consolidated financial statement detail rate effect rate change health care cost trend companys result operation stock base compensation company recognize compensation expense associate issuance equity instrument employee service base type equity instrument fair value estimate date grant blackschole option valuation model combination blackschole option valuation model monte carlo valuation model expense financial statement service period input assumption determine fair value expect life expect volatility riskfree rate expect dividend yield performance share unit fair market value calculate component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model note consolidated financial statement additional information new accounting pronouncement refer note consolidated financial statement recently adopt accounting pronouncement recently issue accounting pronouncement adopt december economic market factor company aware product environment decade policymaker consumer business express concern rise cost health care response concern company longstande policy pricing product responsibly period united states weight average compound annual growth rate company net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi company operate certain country economic condition continue present significant challenge company continue monitor situation appropriate action inflation rate continue effect worldwide economy consequently way company operate company account operation venezuela highly inflationary prior threeyear cumulative inflation rate surpass face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase june united kingdom uk hold referendum voter approve exit european union eu commonly refer brexit march uk formally start process uk leave eu give lack comparable precedent unclear financial trade regulatory legal implication withdrawal uk eu brexit create global political economic uncertainty cause consequence volatility exchange rate interest rate additional cost containment thirdparty payor change regulation company currently believe related effect material impact company consolidate financial position operating result december business company uk subsidiary represent company consolidated asset fiscal month revenue respectively company expose fluctuation currency exchange rate change value dollar compare foreign currency company sale income expense increase decrease translation foreign sale approximately million income million government world consider proposal change tax law include increase decrease exist statutory tax rate change statutory tax rate country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law enact change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change statutory tax rate occur time related expense benefit record material fiscal quarter year law change enact company face worldwide health care change continue result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement health care product change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage result current global economic downturn continue impact company business company operate environment increasingly hostile intellectual property right firm file abbreviate new drug application biosimilar biological product application fda challenge coverage andor validity company patent seek market generic biosimilar form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge result lawsuit generic biosimilar version product issue introduce market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset risk competitor launch generic biosimilar version product issue follow regulatory approval valid patent place information discussion remicade relate case litigation filer abbreviate new drug application note consolidated financial statement legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate company accrue certain litigation matter continue monitor related legal issue adjust accrual new information development accordance accounting standard codification asc litigation regulatory matter currently disclose loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption ability estimate judgment affect factor include damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute numerous party involve company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period note consolidated financial statement information legal proceeding common stock market price company common stock list new york stock exchange symbol jnj february record holders common stock company composite market price range johnson johnson common stock high low high low quarter second quarter quarter fourth quarter yearend close item quantitative qualitative disclosure market risk information call item incorporate reference item management discussion analysis result operation financial condition liquidity capital resource finance market risk report note summary significant accounting policy financial instrument note consolidated financial statement include item report item financial statement supplementary datum index audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement comprehensive income consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm management report internal control financial reporting johnson johnson subsidiaries consolidate balance sheet december january dollar million share share amount note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note prepay expense receivables total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue compensation employee relate obligation accrue taxis income note total current liability longterm debt note defer taxis income note employee relate obligation note longterm taxis payable note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income loss note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson subsidiaries consolidate statement earning dollar share million share amount note sale customer cost product sell gross profit selling marketing administrative expense research development expense inprocess research development interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning net earning share note basic diluted cash dividend share average share outstanding note basic diluted note consolidated financial statement johnson johnson subsidiaries consolidate statement comprehensive income dollar million note net earning comprehensive income loss net tax foreign currency translation security unrealize hold gain loss arise period reclassification earning net change employee benefit plan prior service credit cost net amortization gain loss net amortization effect exchange rate net change derivative hedge unrealize gain loss arise period reclassification earning net change comprehensive income loss comprehensive income tax effect comprehensive income fiscal year end respectively security million million million employee benefit plan million million million derivative hedge million million million note consolidated financial statement johnson johnson subsidiaries consolidate statement equity dollar million note accumulate treasury retain comprehensive common stock stock total earning income issue balance december net earning cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january net earning cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january net earning cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december note consolidated financial statement johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation venezuela adjustments asset writedown net gain sale assetsbusinesse defer tax provision account receivable allowance change asset liability net effect acquisition divestiture increase account receivable decreaseincrease inventory increase account payable accrue liability increase current noncurrent asset increasedecrease current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal assetsbusinesse net acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt net issuance cost retirement longterm debt proceed exercise stock optionsemployee withholding tax stock award net net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest interest net capitalize income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed employee withholding tax stock award conversion debt acquisition fair value asset acquire fair value liability assume noncontrolle interest net cash pay acquisition note consolidated financial statement note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate description company business segment company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device consumer segment include broad range product baby care oral care beauty overthecounter pharmaceutical womens health wound care market product market general public sell retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler hospital health care professional prescription use medical device segment include broad range product orthopaedic surgery cardiovascular diabetes care vision care field distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic accounting standard adopt fiscal second quarter company adopt accounting standard update asu compensation stock compensation improvement employee share base payment accounting report additional tax benefit sharebase compensation vest exercise fiscal year update require excess tax benefit deficiency recognize reduction increase provision taxis income previously company record benefit directly retain earning tax benefit company million fiscal year standard permit retroactive presentation benefit prior fiscal year consolidated statement earning new accounting standard recently adopt accounting standard asu simplifying transition equity method accounting amendment update eliminate requirement investment qualifie use equity method result increase level ownership interest degree influence investor adjust investment result operation retain earning retroactively step step basis equity method effect previous period investment hold amendment update effective entity fiscal year interim period fiscal year begin december amendment apply prospectively effective date increase level ownership interest degree influence result application equity method adoption standard material impact presentation company consolidated financial statement asu simplifying measurement inventory update require inventory measure low cost net realizable value net realizable value estimate selling price ordinary course business reasonably predictable cost completion disposal transportation update effective company annual interim period begin december amendment update apply prospectively update material impact company consolidate financial statement recently issue accounting standard adopt december asu reclassification certain tax effect accumulate comprehensive income update allow reclassification accumulate comprehensive income retain earning strand tax effect result tax cut job act enact december update effective company fiscal year begin december interim period fiscal year early adoption permit company expect standard material impact company consolidated financial statement asu target improvement accounting hedging activity update make financial nonfinancial hedge strategy eligible hedge accounting amend presentation disclosure requirement change company assess effectiveness update effective company fiscal year begin december interim period fiscal year early adoption permit issuance company currently assess impact future adoption standard financial statement asu improve presentation net periodic pension cost net periodic postretirement benefit cost update require employer disaggregate service cost component component net periodic benefit cost npbc addition service cost component eligible capitalization update effective company annual interim period begin december early adoption permit begin annual period financial statement interim annual issue available issuance amendment update apply retrospectively presentation service cost component component npbc income statement prospectively effective date capitalization service cost component npbc asset company assess retroactive restatement methodology impact individual line item consolidate statement earning company expect material impact net earning asu clarify definition business update narrow definition business provide screen determine integrate set asset activity business screen specifie integrate set asset activity business substantially fair value gross asset acquire disposed concentrated single group similar identifiable asset update effective company annual period begin december include interim period annual period early adoption permit update apply prospectively company expect standard material impact company consolidated financial statement asu income taxis intraentity transfer asset inventory update remove current exception gaap prohibit entity recognize current defer income tax expense benefit relate transfer asset inventory consolidated entity current exception defer recognition tax impact transfer inventory consolidated entity sell party remain unaffected amendment update effective public entity annual reporting period begin december result preliminary assessment indicate adoption standard significant impact company financial result company expect record net adjustment defer taxis approximately billion decrease asset approximately billion increase retain earning approximately billion asu lease update require recognition lease asset lease liability balance sheet lease obligation disclose key information leasing arrangement update require recognition lease asset lease liability lessee lease classified operating lease current generally accept accounting principle update effective company annual interim period begin december include interim period fiscal year early application permit company anticipate operating lease result recognition additional asset correspond liability consolidated balance sheet expect standard material impact financial position actual impact depend company lease portfolio time adoption company continue assess implication standard relate financial disclosure asu financial instrument recognition measurement financial asset financial liability amendment update supersede guidance classify equity security readily determinable fair value different category trade availableforsale require equity security measure fair value change fair value recognize net income standard amend financial reporting provide relevant information entitys equity investment reduce number item recognize comprehensive income update effective company annual period begin december interim period annual period adoption standard material impact company consolidated financial statement asu revenue contract customer amendment replace substantially current gaap guidance topic eliminate industryspecific guidance early adoption standard permit original effective date annual period interim reporting period begin december company adopt standard modify retrospective method adoption standard material impact company consolidated financial statement include additional disclosure requirement cash equivalent company classify highly liquid investment state maturity month date purchase cash equivalent highly liquid investment state maturity great month date purchase current marketable security company policy make investment commercial institution investment grade credit rating company invest cash primarily government security obligation corporate debt security money market fund reverse repurchase agreement rra rra collateralized deposit form government security obligation value company record asset liability company permit sell repledge associate collateral company policy collateral equivalent credit rating company utilize party custodian manage exchange fund ensure collateral receive maintain value rra daily basis rra state maturity great month date purchase classify marketable security investment investment classify hold maturity investment report amortize cost realize gain loss report earning investment classify availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income availableforsale security available current operation classify current asset classify long term management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment equity security impairment adjust investment fair value decline market value deem temporary loss security consider temporary loss recognize earning property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow certain event change operate economic condition occur impairment assessment perform recoverability carrying value asset asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate include medicaid estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual sale customer fiscal reporting year promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product include sale customer arrangement evaluate determine appropriate amount defer record reduction revenue shipping handle shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost net realizable value determine firstin firstout method intangible asset goodwill authoritative literature gaap require goodwill intangible asset indefinite life assess annually impairment company complete annual impairment test fiscal fourth quarter future impairment test perform annually fiscal fourth quarter soon warrant purchase inprocess research development account indefinite live intangible asset underlie project complete point intangible asset account definite live intangible asset abandon point intangible asset write partially impair intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset goodwill financial instrument require gaap derivative instrument record balance sheet fair value fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level high priority level low change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution note additional information financial instrument product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information actuarially determine estimate applicable accrual adjust periodically additional information available company accrue estimate legal defense cost need defend matter cost probable reasonably estimate result cost availability factor effective november company cease purchase thirdparty product liability insurance company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization company enter collaborative arrangement typically pharmaceutical biotechnology company develop commercialize drug candidate intellectual property arrangement typically involve party active participant collaboration expose significant risk reward dependent commercial success activity collaboration usually involve activity party include research development marketing selling distribution collaboration require upfront milestone royalty profit share payment contingent occurrence certain future event link success asset development amount collaborative partner relate development activity generally reflect reduction research development expense performance contract development service central company operation general income statement presentation collaboration follow naturetype collaboration statement earning presentation thirdparty sale product sale customer royaltiesmilestone pay collaborative partner postregulatory approval cost product sell royalty receive collaborative partner income expense net upfront payment milestone pay collaborative partner preregulatory research development expense approval research development payment collaborative partner research development expense research development payment receive collaborative partner reduction research development expense milestone capitalize intangible asset amortize cost product sell useful life year present individual project represent great total annual consolidated research development expense company number product compound develop collaboration strategic partner include xarelto codevelope bayer healthcare ag imbruvica develop collaboration comarketed pharmacyclic llc abbvie company advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion respectively income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability future company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position fourth quarter united states enact tcja include provision tax previously undistributed earning foreign jurisdiction company provisionally book billion charge undistribute earning additionally company provisionally record billion defer tax liability foreign local withholding taxis offset billion defer tax asset foreign tax credit repatriation substantially undistributed foreign earning company currently evaluate remain undistributed foreign earning provide defer taxis foreign local withholding tax earning consider indefinitely reinveste unrecorde defer taxis expect material note information income taxis net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis withhold taxis depreciation amortization employee benefit contingency intangible asset liability valuation actual result differ estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week include additional shipping day case case reclassification certain prior period amount reclassify conform current year presentation cash cash equivalent current marketable security end cash cash equivalent current marketable security comprise dollar million current carrying estimate fair cash cash marketable value equivalent security cash security sovereign security reverse repurchase agreement reverse repurchase agreement corporate debt security money market fund time deposit subtotal security sovereign security corporate debt security subtotal available sale total cash cash equivalent current marketable security carry estimate fair value dollar million current carry unrecognized estimate fair marketable gain unrecognized loss value cash equivalent security cash security sovereign security reverse repurchase agreement reverse repurchase agreement corporate debt security money market fund time deposit subtotal unrealized gain unrealize loss security sovereign security corporate debt security equity investment subtotal available sale total cash cash equivalent current marketable security hold maturity investment report amortize cost realize gain loss report earning available sale security report fair value unrealize gain loss report net taxis comprehensive income fair value government security obligation corporate debt security estimate quote broker price significant observable input contractual maturity available sale debt security december follow dollar million cost basis fair value year year year year year total debt security company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution investment grade credit rating inventory end inventory comprise dollar million raw material supply good process finish good total inventory property plant equipment end property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress total property plant equipment gross accumulate depreciation total property plant equipment net company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal property plant equipment cost relate amount accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning intangible asset goodwill end gross net amount intangible asset dollar million intangible asset definite life patent trademark gross accumulate amortization patent trademarks net customer relationship intangible gross accumulate amortization customer relationship intangible net intangible asset indefinite live trademark purchase inprocess research development total intangible asset indefinite live total intangible asset net goodwill december january allocate segment business follow dollar million consumer pharmaceutical medical device total goodwill january goodwill relate acquisition goodwill relate divestiture currency translationother goodwill january goodwill relate acquisition goodwill relate divestiture currency translationother goodwill december weight average amortization period patent trademark customer relationship intangible asset year year respectively amortization expense amortizable asset include cost product sell billion billion billion tax fiscal year end december january january respectively estimate amortization expense succeed year approximate billion tax year intangible asset writedown include income expense net primary driver increase intangible asset goodwill relate actelion acquisition fiscal second quarter result record billion intangible asset billion goodwill intangible asset goodwill amount related actelion acquisition base preliminary purchase price allocation additionally abbott medical optics amo acquisition fiscal quarter result record billion intangible asset billion goodwill intangible asset goodwill amount related amo acquisition base final purchase price allocation note consolidated financial statement additional detail relate acquisition divestiture fair value measurement company use forward foreign exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product thirdparty purchase material denominate foreign currency company use cross currency interest rate swap manage currency risk primarily relate borrowing company use equity collar contract manage exposure market risk associate certain equity investment type derivative designate cash flow hedge additionally company use interest rate swap instrument manage interest rate risk relate fix rate borrowing derivative designate fair value hedge company use forward foreign exchange contract designate net investment hedge additionally company use forward foreign exchange contract offset exposure certain foreign currency asset liabilitie forward foreign exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability company enter derivative financial instrument trade speculative purpose contain credit risk relate contingent feature fiscal second quarter company enter credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement december total collateral pay credit support agreement csa amount million net equity collar contract company pledge underlie hedged marketable equity security counter party collateral ongoing basis company monitor counterparty credit rating company consider credit nonperformance risk low company primarily enter agreement commercial institution investment grade credit rating refer table significant financial asset liability measure fair value contain footnote receivables payable commercial institution december company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap billion billion billion respectively january company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap equity collar contract billion billion billion billion respectively derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction designation cash flow hedge entrance date derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction gain loss associate interest rate swap change fair value hedge debt attributable change interest rate record interest expense period occur gain loss net investment hedge account currency translation account ongoing basis company assess derivative continue highly effective offset change hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning income expense net forward foreign exchange contract cross currency interest rate swap net investment hedge equity collar contract interest rate swap designate fair value hedge hedge ineffectiveness include current period earning interest expense current reporting period hedge ineffectiveness associate interest rate swap material fiscal second quarter company designate euro denominate note issue date range net investment hedge company investment certain international subsidiary use euro functional currency order reduce volatility cause change exchange rate change carry value remeasurement euro note result million unrealized pretax loss fiscal year end december reflect foreign currency translation adjustment consolidated statement comprehensive income change carry value remeasurement euro note result cumulative million unrealized pretax loss hedge inception fiscal year end december reflect foreign currency translation adjustment consolidated statement comprehensive income december balance defer net gain derivative include accumulate comprehensive income million aftertax additional information consolidated statement comprehensive income note company expect substantially amount relate forward foreign exchange contract reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month exclude interest rate contract net investment hedge equity collar contract ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative follow table summary activity relate derivative designate cash flow hedge fiscal year end december january gainloss reclassify gainloss recognize accumulate oci gainloss recognize dollar million accumulate oci income incomeexpense cash flow hedge income statement caption sale customer cost product sell research development expense interest incomeinterest expense net income expense net total amount show table net tax effective portion ineffective portion forward foreign exchange contract cross currency interest rate swap include equity collar contract fiscal year end december january loss million million respectively recognize income expense net relate forward foreign exchange contract designate hedge instrument fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe level high priority level low fair value derivative financial instrument ie forward foreign exchange contract interest rate contract aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company hold equity investment classify level debt security classify level company significant financial asset liability require revised valuation standard recognize fair value follow level input measure fair value level quote price active market identical asset liability level significant observable input level significant unobservable input company significant financial asset liability measure fair value december january follow dollar million level level level total total derivative designate hedge instrument asset forward foreign exchange contract interest rate contract total liability forward foreign exchange contract interest rate contract equity collar contract total derivative designate hedge instrument asset forward foreign exchange contract liability forward foreign exchange contract available sale investment equity investment debt security asset liability classify level exception equity investment million classify level include million million noncurrent asset fiscal year end december january respectively include million million noncurrent liability fiscal year end december january respectively include cross currency interest rate swap interest rate swap classify noncurrent asset carry equity investment million million december january respectively unrealize gain million million december january respectively unrealize loss million million december january respectively classified cash equivalent current marketable security include collateral exchange credit support agreement derivative note financial asset liability hold carrying consolidate balance sheet borrowing component longterm debt follow effective rate effective rate dollar million debenture note debenture note note b euro b euro note note note zero coupon convertible subordinated debenture debenture note note note note note b euro b euro note debenture note note note mm euro mm euro note mm gbp mm gbp note note note note mm euro mm euro note note debenture note note b euro b euro note note note debenture note debenture note note note note note subtotal current portion total longterm debt weight average effective rate translation rate december translation rate january excess fair value carry value debt billion billion fair value longterm debt estimate market price corroborate quote broker price significant observable input company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion end billion borrow commercial paper program billion current portion long term debt remainder principally represent local borrowing international subsidiary company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion end billion borrow commercial paper program billion current portion long term debt remainder principally represent local borrowing international subsidiary aggregate maturity longterm obligation commence dollar million income taxis tax cut job act tcja sec staff accounting bulletin sab december united states enact law new tax legislation refer tcja law include provision comprehensive overhaul corporate income tax code include reduction statutory corporate tax rate effective january new legislation eliminated reduce certain corporate income tax deduction introduce new provision tax certain foreign income previously tax united states tcja include provision tax previously undistribute earning company locate foreign jurisdiction undistribute earning form cash cash equivalent tax rate earning tax rate tax payable year accrue interest december sec provide regulatory guidance accounting impact tcja refer sab guidance sab income tax effect account asc incomplete report provisional base reasonable estimate reasonable estimate subject adjustment measurement period exceed year accounting complete estimate subject finalization management analysis relate certain matter develop interpretation provision tcja change certain estimate amount related earning profit certain subsidiary file tax return result enactment tcja company record provisional tax cost billion fourth quarter provisional charge assess january consist billion charge previously undistribute foreign earning december billion defer tax liability foreign local withholding taxis offset billion defer tax asset foreign tax credit repatriation substantially earning billion tax benefit relate remeasurement defer tax asset liability impact tcja tax reserve billion charge state local taxis repatriation foreign earning determine charge company utilize recent information guidance available relate calculation tax liability impact defer tax asset liability include record foreign local withholding taxis company assess january provisional charge require adjustment change company estimate new guidance available revision provisional charge material company financial result tcja include provision tax global intangible lowtaxed income gilti gilti describe excess shareholder total net foreign income deem return tangible asset provide tcja january response inquirie company fasb issue guidance allow company elect accounting policy treat gilti tax period cost recognize defer tax asset liability basis difference exist expect affect gilti inclusion reversal company provisionally elect treat gilti period expense pende analysis new tax provision provision taxis income consist dollar million currently payable tax international taxis total currently payable defer taxis international taxis total defer provision taxis income comparison income tax expense statutory rate company effective tax rate follow dollar million international earning taxis income tax rate statutory rate international operation research orphan drug tax credit state local manufacturing deduction tax international income tax benefit share base compensation tax benefit assetbusiness disposal tcja impact effective rate period present company subsidiary operate puerto rico tax incentive international operation reflect impact operation jurisdiction statutory tax rate different united states particularly ireland switzerland puerto rico favorable impact effective tax rate compare statutory rate include tax cost relate revaluation defer tax balance relate change belgian statutory tax rate increase tax provision approximately include state local taxis provisionally record tcja provisional charge approximately total effective tax rate effective tax rate increase compare primarily drive enactment tcja united states december enactment tcja result provisional tax charge fourth quarter approximately billion approximately percentage point increase effective tax rate remainder increase tax rate relate remeasurement company defer tax asset belgium result change belgian statutory corporate tax rate enact december offset tax benefit closure company animas insulin pump business decrease effective tax rate compare primarily attributable company adopt new accounting standard report additional tax benefit sharebase compensation vest exercise fiscal year remainder change effective tax rate primarily relate low earning taxis united states settlement uncertain tax position versus decrease effective tax rate compare primarily attributable increase taxable income low tax jurisdiction relative high tax jurisdiction tax benefit result restructure international affiliate item note reflect key driver rate reconciliation temporary difference carryforward follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation nondeductible intangible international rd capitalize tax reserve liabilitie income report tax purpose net operating loss carryforward international undistributed foreign earning miscellaneous international miscellaneous total deferred income taxis company whollyowne international subsidiary cumulative net loss company believe likely subsidiary realize future taxable income sufficient utilize defer tax asset follow table summarize activity relate unrecognized tax benefit dollar million begin year increase relate current year tax position increase relate prior period tax position decreases relate prior period tax position settlement lapse statute limitation end year million decrease relate tcja unrecognized tax benefit billion december recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority irs complete audit tax year currently audit tax year major jurisdiction company conduct business year remain open generally year company believe possible audits complete tax authority jurisdiction month company able provide reasonably reliable estimate time future tax payment relate uncertain tax position company classifie liability unrecognize tax benefit relate interest penalty longterm liabilitie interest expense penalty relate unrecognized tax benefit classify income tax expense company recognize tax interest expense million million million respectively total accrue interest million million respectively employee relate obligation end employee relate obligation record consolidated balance sheet dollar million pension benefit postretirement benefit postemployment benefit defer compensation total employee obligation current benefit payable employee relate obligation noncurrent prepay employee relate obligation million million respectively include asset consolidate balance sheet pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care eligible retire employee dependent international employee cover governmentsponsored program cost company significant retirement plan benefit employee primarily base employee compensation year retirement number year service amendment formula calculate benefit define benefit plan occur benefit employee hire january primarily calculate employee compensation total year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company typically fund retiree health care benefit advance discretion company right modify plan future company december december respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost credit recognize actuarial loss curtailment settlement net periodic benefit cost amount expect recognize net periodic benefit cost come year company define benefit retirement plan postretirement plan dollar million amortization net transition obligation amortization net actuarial loss amortization prior service credit unrecognized gain loss pension plan amortize average remain future service plan plan active employee amortize average life expectancy amortization gain loss benefit plan determine corridor great market value asset accumulate postretirement benefit obligation total unamortized gain loss excess corridor amortize average remain future service prior service costsbenefit pension plan amortize average remain future service plan participant time plan amendment prior service costbenefit benefit plan amortize average remain service eligibility age plan participant time plan amendment follow table represent weightedaverage actuarial assumption retirement plan benefit plan worldwide benefit plan net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation level expect longterm rate return plan asset benefit obligation discount rate rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liabilitie fiscal year company change methodology determine service interest cost single weight average discount rate approach duration specific spot rate yield curve plan liability cash flow management conclude precise estimate prior change methodology company measure service interest cost utilize single weightedaverage discount rate derive yield curve measure plan obligation company account change change accounting estimate accordingly account prospective basis change impact benefit obligation material impact year result expect rate return plan asset assumption represent company assessment longterm return diversify investment portfolio globally assessment determine projection external financial source longterm historical average actual return asset class asset class allocation market follow table display assume health care cost trend rate individual health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement restructure benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss prior service cost credit unrecognized net transition obligation total tax effect accumulate benefit obligation end year company offer voluntary lumpsum payment option predetermine threshold certain eligible employee vest participant qualify define benefit pension plan distribution lumpsum complete end fiscal amount distribute approximately million million respectively distribution plan material impact company financial position retirement plan benefit plan dollar million amount recognize net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rate total lossincome recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company plan continue fund qualified plan comply pension protection act international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain plan fund common practice funding provide economic benefit consequently company pension plan fund company contribute million million international pension plan respectively follow table display fund status company qualified nonqualified pension plan international fund unfunded pension plan december december respectively plan international plan qualified plan nonqualifie plan fund plan unfunded plan dollar million plan asset project benefit obligation accumulate benefit obligation fund status project benefit obligation accumulate benefit obligation plan accumulate benefit obligation excess plan asset accumulate benefit obligation project benefit obligation plan asset billion billion billion respectively end billion billion billion respectively end follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan follow table display project future minimum contribution unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution pension plan oversee local committee board responsible overall administration investment pension plan determine investment policy strategy goal committee board consider factor include local pension rule regulation local tax regulation availability investment vehicle separate account commingle account insurance fund etc funded status plan ratio active retiree duration liability relevant factor include diversification liquidity local market liquidity base currency majority company pension fund open new entrant expect ongoing plan permit investment primarily liquid andor list little reliance illiquid nontraditional investment hedge fund companys retirement plan asset allocation end target allocation follow percent target plan asset allocation worldwide retirement plan equity security debt security total plan asset determination fair value plan asset plan establish welldocumented process determine fair value fair value base quote market price available list price quote available fair value base model primarily use input marketbase independently source market parameter include yield curve interest rate volatilitie equity debt price foreign exchange rate credit curve plan believe valuation method appropriate consistent market participant use different methodology assumption determine fair value certain financial instrument result different estimate fair value report date valuation hierarchy authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe table level high priority level low financial instrument categorization valuation hierarchy base low level input significant fair value measurement follow description valuation methodology investment measure fair value shortterm investment fund cash quote shortterm instrument value closing price hold deposit custodian bank investment investment vehicle value net asset value nav provide administrator fund nav base value underlie asset own fund minus liability divide number share outstanding nav quote price market active classify level government agency security limit number investment value closing price report major market individual security trade quote price available active market investment classify level valuation hierarchy quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow quote market price security available active market classify level debt instrument limit number investment value closing price report major market individual security trade quote price available active market investment classify level quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow classify level level debt instrument price base unobservable input equity security equity security value closing price report major market individual security trade substantially common stock classify level valuation hierarchy commingle fund investment vehicle value nav provide fund administrator nav base value underlie asset own fund minus liability divide number share outstanding asset level category quote market price insurance contract instrument issue insurance company fair value base negotiate value underlie investment hold separate account portfolio consider credit worthiness issuer underlie investment government assetbacke fix income security general insurance contract classify level quote price observable input pricing asset asset represent primarily limit partnership real estate investment commercial loan commercial mortgage classify corporate debt asset exchange list actively trade classified level inactively trade asset classify level follow table set forth retirement plan investment measure fair value december december quote price significant active significant market observable unobservable investment measure identical asset input inputsa net asset value level level level total asset dollar million shortterm investment fund government agency security debt instrument equity security commingle fund insurance contract asset investment fair value activity level asset significant year present company benefit plan unfunded commingle fund level million million shortterm investment fund level million december december respectively fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset december saving plan company voluntary k saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible total company match contribution plan million million million respectively capital treasury stock change treasury stock treasury stock amount million treasury stock share thousand share balance december employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan repurchase common stock balance december aggregate share common stock issue approximately share end cash dividend pay share compare dividend share share october company announce board director approve share repurchase program authorize company purchase billion company share common stock share repurchase program complete july july company announce board director approve share repurchase program authorize company purchase billion company share common stock share repurchase program complete april accumulate comprehensive income loss component comprehensive income loss consist follow total gain accumulate foreign loss currency gainloss employee benefit derivative comprehensive income dollar million translation security plan hedge loss december net change january net change january net change december amount accumulate comprehensive income present net relate tax impact foreign currency translation adjust income taxis relate permanent investment international subsidiary additional detail comprehensive income consolidated statement comprehensive income detail reclassification accumulate comprehensive income gainloss security reclassification release income expense net employee benefit plan reclassification include net periodic benefit cost note additional detail gainloss derivative hedge reclassification earning record account hedge transaction note additional detail international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency majority company subsidiary local currency functional currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate certain balance sheet asset liability current exchange rate account historical rate locate highly inflationary economy translation balance sheet account highly inflationary economy reflect operating result rollforward change foreign currency translation adjustment include note net currency transaction gain loss include income expense loss million million million respectively earning share follow reconciliation basic net earning share dilute net earning share fiscal year end december january january millions share amount basic net earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted net earning share dilute net earning share calculation include dilutive effect convertible debt offset relate reduction interest expense million aftertax year million year million year diluted net earning share calculation include share relate stock option exercise price option average market value company stock rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million respectively approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december dollar million total commitment capital lease significant common stock stock option plan stock compensation agreement december company stockbase compensation plan share outstanding contract company longterm incentive plan longterm incentive plan longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan longterm incentive plan company issue million share common stock plus share cancel expire forfeit issue longterm incentive plan subsequent april share available future grant longterm incentive plan million end compensation cost charge income plan million million million respectively total income tax benefit recognize income statement sharebase compensation cost million million million respectively additional tax benefit million recognize adoption new accounting standard report additional tax benefit sharebase compensation total unrecognized compensation cost million million million respectively weight average period cost recognize year year year respectively sharebase compensation cost capitalize inventory insignificant period company settle employee benefit equity issuance treasury share treasury share replenish year number share settle employee benefit equity issuances stock option stock option expire year date grant vest service period range month year option grant average high low price company common stock new york stock exchange date grant fair value option award estimate date grant blackschole option valuation model use assumption note follow table grant expect volatility represent blend rate year weekly historical overall volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year grant historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life year expect dividend yield summary option activity plan december january january change year end date present aggregate intrinsic weight value share thousand outstanding share average exercise price dollar million share december option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share december total intrinsic value option exercise million million million respectively follow table summarize stock option outstanding exercisable december share thousand outstanding exercisable average exercise average exercise exercise price range option average life price option price average contractual life remain year stock option outstanding january january average life year average life year respectively stock option exercisable january january average price average price respectively restrict share unit performance share unit company grant restrict share unit vest service period range month year company grant performance share unit pay share johnson johnson common stock end threeyear performance period performance share unit vest vest tie completion service period range month year achievement threeyear period equallyweighte goal directly align help drive longterm total shareholder return operational sale adjust operational earning share relative total shareholder return number share actually earn end threeyear period vary base actual performance target number performance share unit grant fourth quarter company modify restrict share unit schedule vest january march modification guarantee minimum aggregate value market value total expect payout award expect vest period commit material company overall financial position summary restrict share unit performance share unit activity plan december present outstanding restricted outstanding performance share thousand share unit share unit share january grant issue canceledforfeitedadjuste share december average fair value restrict share unit grant respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit issue million million million respectively weight average fair value performance share unit grant calculate weighted average fair market value component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model fair value performance share unit issue million million million respectively segment business geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical devices united states international total worldwide total income tax identifiable asset dollar million consumer pharmaceutical medical device total expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant company wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue amount allocate segment include interest income expense general corporate income expense general corporate include cash cash equivalent marketable security pharmaceutical segment include million actelion acquisition relate cost inprocess research development expense million net litigation expense million medical device segment include net litigation expense million restructuring relate charge million asset impairment million primarily relate insulin pump business million amo acquisition relate cost medical device segment include gain billion divestiture codman neurosurgery consumer segment include gain billion divestiture compeed include net litigation expense million restructuring relate charge million medical device segment pharmaceutical segment include positive adjustment billion previous reserve estimate inprocess research development expense million gain divestiture control substance raw material active pharmaceutical ingredient api business certain anesthetic product europe medical device segment include restructure relate charge million intangible asset writedown million related acclarent synthe integration cost million million expense cost associate depuy asrtm hip program include million inprocess research development expense comprise million million pharmaceutical medical device segment respectively include net litigation expense million comprise million pharmaceutical segment million medical device segment include gain litigation settlement agreement guidant million medical device segment include gain billion divestiture cordis business pharmaceutical segment include gain million divestiture nucynta positive adjustment billion previous reserve estimate include manage medicaid rebate consumer segment include gain million divestiture splenda brand longlive asset include property plant equipment net respectively intangible asset goodwill net respectively select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share datum q u arter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical medical device total sale gross profit earning provision taxis income net earning loss basic net earning loss share dilute net earning loss share quarter include restructure charge million aftertax million beforetax amo acquisition relate cost million aftertax million beforetax second quarter include net litigation expense million aftertax million beforetax actelion acquisition relate cost million aftertax million beforetax restructuring charge million aftertax million beforetax asset impairment charge million aftertax million beforetax quarter include net litigation expense million aftertax million beforetax actelion acquisition relate cost million tax million beforetax restructuring charge million aftertax million beforetax fourth quarter include net litigation expense million aftertax million beforetax actelion acquisition relate cost million aftertax million beforetax restructuring charge million aftertax million beforetax inprocess research development expense million aftertax million beforetax aftertax benefit million related insulin pump business additionally fourth quarter include provisional charge billion recently enact tax legislation quarter include restructure charge million aftertax million beforetax net litigation expense million aftertax million beforetax second quarter include restructure charge million aftertax million beforetax net litigation expense million aftertax million beforetax quarter include restructure charge million aftertax million beforetax net litigation expense million aftertax million beforetax fourth quarter include restructure charge million aftertax million beforetax net litigation expense million aftertax million beforetax business combination divestiture certain business acquire million cash million liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include actelion ltd establish lead franchise differentiate innovative product pulmonary arterial hypertension pah abbott medical optics amo whollyowne subsidiary abbott laboratory include ophthalmic product relate cataract surgery laser refractive surgery consumer eye health neuravi limit privatelyheld medical device company develop market medical device neurointerventional therapy tearscience inc manufacturer product dedicate treat meibomian gland dysfunction sightbox inc privatelyheld company develop subscription vision care service connect consumer eye care professional supply contact lense torax medical inc privatelyheld medical device company manufacture markets linx reflux management system surgical treatment gastroesophageal reflux disease megadyne medical products inc privatelyheld medical device company develop manufacture market electrosurgical tool excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition actelion ltd value iprd calculate cash flow projection discount inherent risk project company complete acquisition actelion ltd cash tender offer switzerland share amount billion net cash acquire transaction immediately prior completion acquisition actelion spin drug discovery operation early stage clinical development asset newly create swiss biopharmaceutical company idorsia ltd shares idorsia list swiss exchange company currently hold share idorsia right additional idorsia equity convertible loan principal approximately billion convertible loan convert idorsia share follow aggregate shareholding idorsia share result certain shareholder hold issue idorsia shares ii balance remain business day maturity date convertible loan year term idorsia undergo change control transaction investment idorsia record cost method investment asset company consolidated balance sheet company exercise option acquire act product idorsia develop resistant hypertension currently phase clinical development company enter agreement provide idorsia swiss franc denominate credit facility approximately million december idorsia draw down credit facility actelion enter transitional service agreement idorsia actelion establish lead franchise differentiate innovative product pulmonary arterial hypertension pah highly complementary exist portfolio company addition actelion specialty inmarket medicine latestage product consistent company effort grow attractive complementary therapeutic area serve patient illness significant unmet medical need company finalize allocation purchase price individual asset acquire liability assume allocation purchase price include current period balance sheet base good estimate management preliminary subject change assist management allocation company engage valuation specialist prepare appraisal company finalize amount recognize information necessary complete analysis obtain company expect finalize amount soon possible later year acquisition date follow table present preliminary amount recognize asset acquire liability assume actelion acquisition date adjustment december dollar millions june december cash cash equivalent inventory account receivable current asset property plant equipment goodwill intangible asset defer taxis noncurrent asset total asset acquire current liability defer taxis noncurrent liability total liability assume net asset acquire include adjustment million writeup acquire inventory estimate fair value subsequent date acquisition adjustment billion defer taxis billion current liability offset goodwill asset acquire record pharmaceutical segment acquisition actelion result approximately billion goodwill goodwill primarily attributable synergy expect arise acquisition goodwill expect deductible tax purpose purchase price allocation identifiable intangible asset follow dollar million intangible asset definite life patent trademark total amortizable intangible inprocess research development total intangible asset patent trademark acquire comprise develop technology weight average life year primarily base patent life market product intangible asset definite life assign asset life range year inprocess research development intangible asset value technology program unapprove product value iprd calculate probability adjust cash flow projection discount risk inherent project discount rate apply acquisition account acquisition method accordingly result operation actelion report company financial statement begin june date acquisition year end december total sale net loss actelion date acquisition billion billion respectively follow table provide pro forma result operation fiscal year end december january actelion acquire january pro forma result include effect certain purchase accounting adjustment estimate change depreciation amortization expense acquire tangible intangible asset pro forma result include anticipate cost saving effect plan integration actelion accordingly amount necessarily indicative result acquisition occur date indicate occur future unaudited pro forma consolidated result dollar million share datum net sale net earning dilute net earning common share company record actelion acquisition relate cost tax approximately billion record incomeexpense cost product sell company acquire abbott medical optics amo whollyowne subsidiary abbott laboratorie billion net cash acquire acquisition include ophthalmic product relate cataract surgery laser refractive surgery consumer eye health net purchase price primarily record amortizable intangible asset billion goodwill billion weight average life total amortizable intangible majority customer relationship approximately year goodwill primarily attributable synergy expect arise business acquisition deductible tax purpose intangible asset goodwill amount base final purchase price allocation asset acquire record medical device segment certain business acquire million cash million liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include vogue international llc privatelyheld company focus marketing development distribution salon influence nature inspire hair care personal product neuwave medical inc privatelyheld medical device company manufacture market minimally invasive soft tissue microwave ablation system neostrata company inc global leader dermocosmetic global right commercialization rhinocort allergy spray outside united states excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill net purchase price vogue international llc billion primarily record amortizable intangible asset billion goodwill billion weight average life billion total amortizable intangible approximately year trademark asset value determine definite life range year majority year goodwill primarily attributable synergy expect arise business acquisition expect deductible tax purpose asset acquire record consumer segment certain business acquire million cash million liability assume assumed liability primarily represent fair value contingent consideration million acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include xo limited privatelyheld biopharmaceutical company develop antithrombin antibody novira therapeutics inc privately hold clinicalstage biopharmaceutical company develop innovative therapy curative treatment chronic hepatitis b virus infection excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition xo limited novira therapeutics inc value iprd calculate cash flow projection discount inherent risk project iprd relate acquisition xo limited million associate recombinant human antibody develop mimic activity human antibody appear produce anticoagulated state predisposition bleed probability success factor reflect inherent clinical regulatory risk discount rate apply iprd relate acquisition novira therapeutics inc million associate lead candidate nvr investigational small molecule directacte antiviral oral administration patient hbv inhibit hbv core capsid protein probability success factor reflect inherent clinical regulatory risk discount rate apply company record charge impairment iprd relate acquisition novira therapeutics inc impairment result cancellation product development safety concern company complete acquisition synthes inc purchase price billion cash stock connection acquisition synthes inc company enter accelerated share repurchase asr agreement company settle remain liability asr agreement company believe transactions asr agreement series relate internal transaction consummate tax efficient manner accordance applicable law possible internal revenue service assert contrary position challenge transaction tax perspective challenge total purchase price synthe share treat subject applicable tax approximately statutory rate company plus interest exception actelion ltd acquisition supplemental pro forma information accordance gaap standard relate business combination goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position fiscal quarter company announce engaging process evaluate potential strategic option johnson johnson diabetes care company specifically lifescan inc animas corporation calibra medical inc strategic option include formation operate partnership joint venture strategic alliance sale business alternative separately fiscal second quarter company record impairment charge billion primarily relate insulin pump business fiscal fourth quarter company announce decision exit animas insulin pump business company continue evaluate potential strategic option lifescan inc determine good opportunity drive future growth maximize shareholder value asset hold sale december relate announcement company divestiture primarily include codman neurosurgery business integra lifescience holdings corporation divestiture compeed hra pharma pretax gain divestiture approximately billion company divestiture include control substance raw material active pharmaceutical ingredient api business certain anesthetic product europe certain nonstrategic consumer brand pretax gain divestiture approximately billion company divestiture include cordis business cardinal health splenda brand heartland food product group license right nucynta tapentadol nucyntaer tapentadol extendedrelease tablet nucynta tapentadol oral solution pretax gain divestiture approximately billion legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate december company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption ability estimate judgment affect factor include damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute numerous party involve company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period product liability johnson johnson certain subsidiary involve numerous product liability claim lawsuit involve multiple product claimant case seek substantial compensatory available punitive damage company believe substantial defense feasible predict ultimate outcome litigation company establish accrual product liability claim lawsuit compliance asc base currently available information case limited company accrue estimate legal defense cost need defend matter cost probable reasonably estimate certain matter company accrue additional amount estimate cost associate settlement damage loss extent adverse verdict render company company record accrual loss determine probable reasonably estimate product liability accrual represent project product liability thousand claim world different litigation environment different fact pattern change accrual require future additional information available significant case include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic mesh risperdal xarelto body powder contain talc primarily johnson baby powder invokana december approximately plaintiff direct claim pende lawsuit injury allegedly depuy asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic mesh respect risperdal respect xarelto respect body powder contain talc respect invokana august depuy orthopaedics inc depuy announce worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system hip replacement surgery claim personal injury depuy johnson johnson number pende lawsuit expect fluctuate certain lawsuit settle dismiss additional lawsuit file case file federal court united states organize multidistrict litigation united states district court northern district ohio litigation file country outside united states primarily united kingdom canada australia ireland germany italy november depuy reach agreement court appoint committee lawyer represent asr hip system plaintiff establish program settle claim eligible asr hip patient unite states surgery replace asr hips know revision surgery august depuy reach additional agreement february march extend settlement program include asr hip patient revision surgery august prior february settlement program resolve claim expect recent extension bring resolution significant asr hip litigation activity united states lawsuit united states remain settlement program address litigation outside united states australia class action settlement reach resolve claim majority asr hip patient country company continue receive information respect potential additional cost associate recall worldwide basis company establish accrual cost associate united states settlement program depuy asr hiprelated product liability litigation claim personal injury depuy orthopaedics inc johnson johnson relate pinnacle acetabular cup system hip replacement surgery number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court northern district texas litigation file state court country outside united states primarily united kingdom united kingdom trial ongoing common issue liability decision expect half company establish accrual defense cost connection product liability litigation associated pinnacle acetabular cup system claim personal injury ethicon inc ethicon johnson johnson arising ethicon pelvic mesh device treat stress urinary incontinence pelvic organ prolapse company continue receive information respect potential cost additional case case file federal court united states organize multidistrict litigation united states district court southern district west virginia company settled resolve majority united states case cost associate settlement reflect company accrual addition class action individual personal injury case claim commence country outside united states include claim case united kingdom netherlands belgium class action israel australia canada seek damage allege injury result ethicon pelvic mesh device australia trial class action issue ongoing decision expect company establish accrual respect product liability litigation associate ethicon pelvic mesh product claim personal injury janssen pharmaceuticals inc johnson johnson arising use risperdal indicate treatment schizophrenia acute manic mixed episode associate bipolar disorder irritability associate autism relate compound lawsuit primarily file state court pennsylvania california missouri action pende court united states canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company establish accrual respect product liability litigation associate risperdal claim personal injury arise use xarelto oral anticoagulant janssen pharmaceuticals inc jpi johnson johnson jpi collaboration partner xarelto bayer ag certain affiliate number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court eastern district louisiana addition case file state court united states case consolidate state mass tort litigation philadelphia pennsylvania coordinate proceeding delaware california missouri class action lawsuit file canada company establish accrual defense cost connection product liability litigation associate xarelto claim personal injury johnson johnson consumer inc johnson johnson arising use body powder contain talc primarily johnson baby powder number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case lawsuit primarily file state court missouri new jersey california case file federal court united states organize multidistrict litigation united states district court district new jersey company establish accrual defense cost connection product liability litigation associate body powder contain talc claim personal injury number johnson johnson company include janssen pharmaceuticals inc johnson johnson arising use invokana prescription medication indicate improve glycemic control adult type diabete number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court district new jersey case file state court pennsylvania california new jersey class action lawsuit file canada company establish accrual respect product liability litigation associate invokana intellectual property certain subsidiary johnson johnson subject time time legal proceeding claim relate patent trademark intellectual property matter arise business matter involve challenge coverage andor validity patent product allegation certain company product infringe patent party subsidiary believe substantial defense challenge allegation respect significant patent assurance outcome matter loss case adversely affect ability subsidiary sell product result loss sale loss market exclusivity require payment past damage future royalty result noncash impairment charge associate intangible asset significant matter describe medical device june rembrandt vision technology lp rembrandt file patent infringement lawsuit johnson johnson vision care inc jjvci united states district court eastern district texas allege jjvci manufacture sale acuvue advance acuvue oasys hydrogel contact lense infringe rembrandts united states patent seek monetary relief case transfer united states district court middle district florida trial resulted verdict noninfringement subsequently uphold appeal july rembrandt seek new trial base alleged new evidence district court deny april court appeal overturn ruling remand case district court new trial new trial hold august jury return verdict noninfringement favor jjvci rembrandt appeal verdict united states court appeal federal circuit march medinol ltd medinol file patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york allege cordiss sale cypher cypher select stent united states willfully infringe medinol patent direct geometry articulate stent medinol seek damage attorney fee trial january district court dismiss case find medinol unreasonably delay bring claim lache defense september district court deny motion medinol vacate judgment grant new trial medinol appeal decision united states court appeal federal circuit dismiss appeal order file petition review united states supreme court march united states supreme court hold laches defense available patent case remand case united states court appeal federal circuit consider medinol appeal medinol entitle seek new trial cordis divest company retain liability result case november medidea llc medidea file patent infringement lawsuit depuy orthopaedics inc united states district court northern district illinois allege infringement attune knee system medidea allege infringement united states patent nos relate posterior stabilize knee system specifically medidea allege sofcamtm contact feature attune posterior stabilize knee product infringe patentsinsuit medidea seek monetary damage injunctive relief june case transfer united states district court district massachusetts december depuy synthes products inc file petition inter parte review united states patent trademark office seek invalidate patent december ethicon endosurgery inc ethicon endosurgery llc know ethicon llc sue covidien inc united states district court district massachusetts seek declaration united states patent nos patent patent invalid infringe ethicon enseal x large jaw tissue sealer product april covidien lp covidien sales llc covidien ag collectively covidien answer counterclaim deny allegation assert willful infringement patent patent united states patent nos seek damage injunction covidien file motion preliminary injunction deny october trial schedule september november board regents university texas system tissuegen inc file lawsuit united states district court western district texas ethicon inc ethicon llc allege manufacture sale vicryl plus antibacterial suture monocryl plus antibacterial suture infringe plaintiff united states patent nos direct implantable polymer drug release biodegradable fiber contain therapeutic agent pharmaceutical april morphosys ag german biotech company file patent infringement lawsuit janssen biotech inc jbi genmab inc genmab collectively genmab united states district court district delaware morphosys allege jbis manufacture sale darzalex daratumumab willfully infringe morphosys united states patent nos morphosys seek money damage jbi license patent commercial right darzalex genmab trial case schedule commence february august sandoz ltd hexal ag collectively sandoz file lawsuit english high court gd searle llc pfizer company janssen sciences ireland uc jsi allege searle supplementary protection certificate spcgb spc exclusively license jsi invalid revoke janssencilag limited sell prezista darunavir united kingdom pursuant license october searle jsi counterclaimed sandoz threaten infringement spc base statement plan launch generic darunavir united kingdom sandoz admit generic darunavir product infringe spc find valid searle jsi seek order enjoin sandoz market generic darunavir expiration spc follow trial april court enter decision hold spc valid grant final injunction sandoz appeal court decision injunction stay pende appeal january court refer issue appeal court justice european union cjeu stay proceeding pende cjeus rule issue remicade relate case united states proceeding september janssen biotech inc jbi nyu langone medical center nyu receive office action united states patent trademark office uspto reject claim united states patent relate remicade infliximab patent reexamination proceeding institute party patent expire september coowne jbi nyu nyu grant jbi exclusive license nyus right patent follow office action patent examiner include rejection response jbi uspto issue action maintain rejection patent jbi file notice appeal uspto patent trial appeal board board issue decision november uphold examiner rejection january united states court appeal federal circuit affirm board decision august celltrion healthcare co ltd celltrion inc collectively celltrion file application united states food drug administration fda approval sell infliximab biosimilar march jbi file lawsuit united states district court district massachusetts celltrion hospira healthcare corporation hospira exclusive marketing right celltrion infliximab biosimilar united states seek thing declaratory judgment biosimilar product infringe potentially infringe jbi patent include patent united states patent patent august district court grant celltrion hospira motion summary judgment invalidity patent jbi appeal decision united states court appeal federal circuit january federal circuit dismiss appeal moot base affirmance board reexamination decision june jbi file additional patent infringement lawsuit assert patent celltrion hospira united states district court district massachusetts hyclone laboratories inc manufacturer cell culture medium celltrion use biosimilar product united states district court district utah patent assert exist lawsuit celltrion additional lawsuit expand claim include sale united states celltrion biosimilar product manufacture cell culture medium united states additional lawsuit celltrion consolidate exist lawsuit discuss hospira move dismiss count lawsuit relate patent celltrion motion dismiss count lawsuit relate patent failure join coowner patent plaintiff deny october trial schedule begin july litigation hyclone utah stay pende outcome massachusetts action fda approve celltrion infliximab biosimilar sale united states april hospira parent company pfizer inc launch celltrion infliximab biosimilar united states late april jbi receive notice fda approve marketing application submit samsung bioepis co ltd samsung sale infliximab biosimilar united states jbi file patent infringement lawsuit samsung united states district court district new jersey allege sale biosimilar product infringe jbis patent july samsung launch biosimilar product commercialize merck united states november jbi voluntarily dismiss lawsuit litigation filer abbreviate new drug application anda follow summarize lawsuit pende generic company file abbreviate new drug application andas fda undertake similar regulatory process outside united states seek market generic form product sell subsidiary johnson johnson prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability applicable patent event subsidiarie successful action statutory month stay andas expire united states district court ruling obtain thirdparty company involve ability approval fda introduce generic version product issue market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset addition time time subsidiary settle action settlement involve introduction generic version product issue market prior expiration relevant patent inter part review ipr process united states patent trademark office uspto create america invents act generic company conjunction anda lawsuit challenge patent hold company subsidiary zytiga july janssen biotech inc janssen oncology inc janssen research development llc collectively janssen btg international ltd btg initiate patent infringement lawsuit united states district court district new jersey number generic company certain affiliate andor supplier file anda seek approval market generic version zytiga mg expiration united states patent patent generic company currently include amneal pharmaceutical llc amneal pharmaceutical new york llc collectively amneal apotex inc apotex corp collectively apotex citron pharma llc citron dr reddys laboratories ltd dr reddys laboratories inc collectively dr reddys mylan pharmaceuticals inc mylan inc collectively mylan par pharmaceuticals inc par pharmaceutical companies inc collectively par sun pharmaceutical industries ltd sun pharmaceuticals industries inc collectively sun teva pharmaceuticals usa inc teva wockhardt bio ag wockhardt usa llc wockhardt ltd collectively wockhardt westward pharmaceutical corp westward hikma pharmaceuticals llc hikma february court hear oral argument motion summary judgment noninfringement file certain defendant party await decision decision unfavorable stay lift generic version zytiga enter market janssen btg initiate patent infringement lawsuit united states district court district new jersey amerigen pharmaceuticals limited amerigen glenmark pharmaceuticals inc june file anda seek approval market generic version zytiga expiration patent august janssen btg file additional jurisdictional protective lawsuit mylan defendant united states district court northern district west virginia stay august janssen btg initiate patent infringement lawsuit united states district court district new jersey teva file anda seek approval market generic version zytiga mg expiration patent january janssen dismiss lawsuit sun withdraw anda lawsuit janssen seek order enjoin defendant market generic version zytiga expiration patent generic company include amerigen argentum pharmaceuticals llc argentum mylan wockhardt actavis amneal dr reddys sun teva west ward hikma file petition inter parte review ipr uspto seek invalidate patent january uspto issue decision invalidate patent janssen appeal decision ipr decision bind district court pende litigation october janssen inc janssen oncology inc collectively janssen initiate notice application section patent medicine notice compliance regulation teva canada limited teva minister health canada response teva filing abbreviate new drug submission and seek approval market generic version zytiga mg zytiga mg expiration canadian patent november janssen initiate notice application section patent medicine notice compliance regulation apotex inc apotex minister health canada response apotexs filing abbreviate new drug submission and seek approval market generic version zytiga expiration canadian patent notice application janssen seek order prohibit minister health issuing notice compliance respect teva apotex and expiration janssen patent complera august september janssen pharmaceutica nv janssen sciences ireland uc collectively janssen gilead sciences inc gilead sciences ireland uc collectively gilead initiate patent infringement lawsuit united states district court district delaware district west virginia respectively mylan inc mylan pharmaceuticals inc collectively mylan file anda seek approval market generic version complera expiration united states patent nos july west virginia lawsuit dismiss prejudice stipulation party delaware lawsuit janssen gilead amend complaint add claim patent infringement respect united states patent nos november party enter settlement agreement xarelto begin october janssen pharmaceuticals inc jpi bayer pharma ag bayer intellectual property gmbh collectively bayer file patent infringement lawsuit united states district court district delaware number generic company file anda seek approval market generic version xarelto expiration bayers united states patent nos relate xarelto jpi exclusive sublicensee assert patent follow generic company name defendant aurobindo pharma limited aurobindo pharma usa inc collectively aurobindo breckenridge pharmaceutical inc breckenridge invagen pharmaceuticals inc invagen micro labs usa inc micro labs ltd collectively micro mylan pharmaceuticals inc mylan prinston pharmaceuticals inc sigmapharm laboratory llc sigmapharm torrent pharmaceutical limited torrent pharma inc collectively torrent defendant mylan sigmapharm agree case stay bind outcome final judgment render defendant trial schedule march begin april jpi bayer intellectual property gmbh bayer ag collectively bayer ag file patent infringement lawsuit united states district court district delaware number generic company file anda seek approval market generic version xarelto expiration bayer ags united states patent relate xarelto follow generic company name defendant alembic pharmaceutical limit alembic global hold sa alembic pharmaceuticals inc aurobindo breckenridge invagen lupin limited lupin pharmaceuticals inc collectively lupin micro mylan sigmapharm taro pharmaceutical industry ltd taro pharmaceuticals usa inc collectively taro torrent lupin counterclaim declaratory judgment noninfringement invalidity united states patent lupin dismiss counterclaim provide covenant sue patent aurobindo taro torrent micro agree case stay bind outcome final judgment render defendant case consolidate discovery trial currently set trial april lawsuit jpi seek order enjoin defendant market generic version xarelto expiration relevant patent prezista september janssen sciences ireland uc janssen product lp collectively janssen initiate patent infringement lawsuit united states district court district new jersey aurobindo pharma ltd aurobindo pharma usa inc collectively aurobindo file anda seek approval market generic version prezista expiration united states patent nos january party enter settlement agreement november janssen inc initiate notice application section patent medicine notice compliance regulation apotex inc apotex minister health canada response apotexs filing abbreviate new drug submission and seek approval market generic version prezista expiration canadian patent nos own united states board trustee university illinois janssen seek order prohibit minister health issuing notice compliance respect apotex and expiration relevant patent risperdal consta november united states patent trademark office uspto institute inter parte review file luye pharma group ltd luye pharma usa ltd sandong luye pharmaceutical co ltd nanjing luye pharmaceutical co ltd seek invalidate united states patent relate risperdal consta janssen pharmaceuticals inc market risperdal consta pursuant license alkerme pharma ireland ltd november uspto issue decision uphold validity patent invokanainvokamet begin july janssen pharmaceuticals inc janssen research development llc cilag gmbh international janssen pharmaceutica nv collectively janssen mitsubishi tanabe pharma corporation mtpc file patent infringement lawsuit united states district court district new jersey united states district court district colorado united states district court district delaware number generic company file anda seek approval market generic version invokana andor invokamet expiration mtpcs united states patent nos andor relate invokana invokamet janssen exclusive licensee assert patent follow generic company name defendant apotex inc apotex corp apotex aurobindo pharma usa inc aurobindo macleods pharmaceuticals ltd macleods pharma usa inc invagen pharmaceuticals inc invagen prinston pharmaceuticals inc dr reddys laboratories inc dr reddys laboratories ltd hetero usa inc hetero labs limited unitv hetero labs limited msn laboratory private ltd msn pharmaceuticals inc laurus labs ltd indoco remedies ltd zydus pharmaceuticals usa inc zydus sandoz inc sandoz teva pharmaceuticals usa inc lupin ltd lupin pharmaceuticals inc begin july janssen mtpc file patent infringement lawsuit united states district court district new jersey united states district court district colorado sandoz invagen file anda seek approval market generic version invokana andor invokamet expiration mtpcs united states patent patent relate invokana invokamet zydus file anda seek approval market generic version invokana invokamet expiration patent mtpc united states patent relate invokana invokamet mtpcs united states patent relate invokamet aurobindo file anda seek approval market generic version invokana expiration patent patent relate invokana janssen exclusive licensee assert patent october colorado lawsuit sandoz dismiss december delaware lawsuit apotex teva dismiss lawsuit janssen mtpc seek order enjoin defendant market generic version invokana andor invokamet expiration relevant patent veletri july actelion pharmaceuticals ltd actelion initiate patent infringement lawsuit united states district court district new jersey sun pharmaceutical industries inc sun pharmaceutical industry limit collectively sun pharmaceutical file anda seek approval market generic version veletri expiration united states patent actelion seek order enjoin sun pharmaceutical marketing generic version veletri expiration patent trial schedule commence june opsumit january actelion pharmaceuticals ltd actelion initiate patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc zydus amneal pharmaceutical llc amneal file anda seek approval market generic version opsumit expiration united states patent lawsuit actelion seek order enjoin zydus amneal marketing generic version opsumit expiration patent invega sustenna january janssen pharmaceutica nv janssen pharmaceuticals inc collectively janssen initiate patent infringement lawsuit united states district court district new jersey teva pharmaceuticals usa inc teva file anda seek approval market generic version invega sustenna expiration united states patent lawsuit janssen seek order enjoin teva market generic version invega sustenna expiration patent imbruvica begin january pharmacyclic llc pharmacyclic janssen biotech inc janssen file patent infringement lawsuit united states district court district delaware number generic company file anda seek approval market generic version imbruvica expiration pharmacyclic united states patent nos andor relate imbruvica janssen exclusive licensee assert patent follow generic company name defendant cipla limited cipla usa inc cipla fresenius kabi usa llc fresenius kabi usa inc fresenius kabi oncology limit fresenius kabi sandoz inc lek pharmaceutical dd sandoz shilpa medicare limited shilpa sun pharma global fze sun pharmaceutical industry limited sun teva pharmaceuticals usa inc teva pharmaceutical industry limit teva zydus worldwide dmcc cadila healthcare limited zydus lawsuit pharmacyclic janssen seek order enjoin defendant market generic version imbruvica expiration relevant patent government proceeding like company pharmaceutical medical device industry johnson johnson certain subsidiary subject extensive regulation national state local government agency united states country operate result interaction government agency ongoing significant litigation bring investigation conduct government agency list possible criminal charge substantial fine andor civil penalty damage result government investigation litigation average wholesale price awp litigation johnson johnson pharmaceutical subsidiary jj awp defendant numerous pharmaceutical company name defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue payor allege awps calculate provider reimbursement level plaintiff case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation united states district court district massachusetts claim jj awp defendant ultimately dismiss jj awp defendant prevail case bring commonwealth pennsylvania awp case resolve court order settlement case remain pende case bring illinois party await assignment trial date new jersey putative class action base awp allegation pende centocor inc ortho biotech inc janssen biotech inc johnson johnson alza corporation opioid litigation begin continue present johnson johnson janssen pharmaceuticals inc jpi pharmaceutical company name numerous lawsuit bring certain state local government relate marketing opioid include duragesic nucynta nucynta er date complaint pharmaceutical company include johnson johnson jpi file state court state attorney general louisiana mississippi missouri new mexico ohio oklahoma complaint manufacturer file state federal court city county local government agency follow state arkansas california connecticut florida georgia illinois kentucky louisiana mississippi missouri nevada new hampshire new jersey new mexico new york ohio oklahoma oregon pennsylvania tennessee texas washington west virginia actions allege variety claim relate opioids marketing practice include false advertising unfair competition public nuisance consumer fraud violation deceptive act practice false claim unjust enrichment suit generally seek penalty andor injunctive monetary relief case early stage litigation october johnson johnson jpi serve motion consolidate pende matter federal multi district litigation southern district ohio december mdl approve northern district ohio approximately case transfer mdl johnson johnson jpi pharmaceutical company receive subpoena request information relate opioids marketing practice follow state attorney general alaska indiana new hampshire new jersey tennessee washington september johnson johnson jpi contacted texas colorado attorney general office behalf approximately state multistate attorney general investigation multistate coalition serve johnson johnson jpi subpoenas investigation johnson johnson jpi receive request information rank minority member united states senate committee homeland security governmental affair sale marketing educational strategy relate promotion opioid use august depuy orthopaedics inc depuy inc depuy synthes inc johnson johnson services inc receive informal request united states attorney office district massachusetts civil division united states department justice united states production material relate depuy asr xl hip device july united states notify united states district court district massachusetts decline intervene qui tam case file pursuant false claim act company february district court grant company motion dismiss prejudice unseal qui tam complaint deny qui tam relator request leave file amend complaint qui tam relator appeal case united states court appeal circuit july circuit affirm district court dismissal reverse affirm decision deny relator request file amend complaint relator remain claim pende district court october group state attorney general issue civil investigative demand relate development sale market depuy orthopaedics inc hip product state seek monetary injunctive relief depuy orthopaedics inc enter tolling agreement state july oregon department justice investigate matter independently state announce settlement asr xl hip device investigation state oregon october johnson johnson contact california attorney general office multistate attorney general investigation market surgical mesh product hernia urogynecological purpose johnson johnson subsidiary ethicon inc ethicon johnson johnson ethicon enter series tolling agreement state district columbia participate multistate investigation respond civil investigative demand serve certain participate state state seek monetary injunctive relief california washington file civil complaint johnson johnson ethicon inc ethicon llc allege violation consumer protection statute similar complaint file company kentucky august mississippi october johnson johnson ethicon enter new tolling agreement remain states district columbia december therakos inc therakos subsidiary johnson johnson orthoclinical diagnostics inc ocd franchise receive letter civil division united states attorney office eastern district pennsylvania inform therakos united states attorney office investigate sale marketing uvadex methoxsalen uvar xts cellex systems period present united states attorney office request ocd johnson johnson preserve document relate investigation therakos subsequently acquire affiliate gore capital partner iii lp january ocd divest june follow divestiture ocd johnson johnson retain ocds portion liability result investigation activity occur prior sale therakos march march united states attorney office request johnson johnson produce certain document johnson johnson cooperate request june mississippi attorney general file complaint chancery court judicial district hind county mississippi johnson johnson johnson johnson consumer companies inc johnson johnson consumer inc jjci complaint allege defendant fail disclose allege health risk associate female consumer use talc contain johnson baby powder johnson shower shower product long sell jjci seek injunctive monetary relief party agree adjourn trial date currently expect trial reschedule fall march janssen pharmaceuticals inc jpi receive civil investigative demand united states attorney office southern district new york relate jpis contractual relationship pharmacy benefit manager period january present regard certain jpi pharmaceutical product demand issue connection investigation false claim act january janssen pharmaceuticals inc jpi receive civil investigative demand united states department justice relate allegation concern sale marketing practice olysio december johnson johnson jpi serve whistleblow lawsuit file united states district court central district california allege offlabel promotion olysio additional product include nucynta xarelto levaquin remicade time federal state government decline intervene lawsuit relate civil investigative demand prosecute company employee jpi file motion dismiss united states district court central district california january february johnson johnson receive subpoena united states attorney office district massachusett seek production record pertain payment c charitable organization provide financial assistance medicare patient multiple pharmaceutical company publicly report receipt subpoenas ongoing inquiry similar describe actelion pharmaceutical inc actelion receive subpoena followup request june december united states attorney office district massachusetts subpoena seek production record pertain actelion payment c charitable organization provide financial assistance medicare patient march janssen biotech inc receive civil investigative demand united states department justice false claim act investigation concern management advisory service provide rheumatology gastroenterology practice purchase remicade simponi aria april september johnson johnson receive subpoenas united states attorney district massachusetts seek document broadly relate pharmaceutical copayment support program darzalex olysio remicade simponi stelara zytiga subpoena seek document relate average manufacturer price good price reporting center medicare medicaid services relate product rebate payment state medicaid agencies june johnson johnson receive subpoena united states attorney office district massachusett seek information practice pertain sterilization depuy synthes inc spinal implant hospital boston interaction company employee physician hospitals johnson johnson produce document response subpoena time time johnson johnson receive request variety united states congressional committee produce information relevant ongoing congressional inquiry policy johnson johnson cooperate inquiry produce request information general litigation june follow public announcement orthoclinical diagnostics inc ocd receive grand jury subpoena united states department justice antitrust division connection investigation closed multiple class action complaint file ocd direct purchaser seek damage allege price fixing case consolidated pretrial purpose united states district court eastern district pennsylvania blood reagent antitrust litigation follow appeal reversal initial grant motion class certification remand district court october grant motion plaintiff class certification july court issue opinion grant deny ocd motion summary judgment court grant summary judgment concern allegation price fixing deny summary judgment concern allegation price fix trial set june ocd divested johnson johnson retain liability result case june depuy orthopaedics inc depuy file suit orthopaedic hospital oh united states district court northern district indiana seek declaratory judgment depuy owe oh royalty development agreement january oh file breach contract case california federal court later consolidate indiana case february oh bring suit patent infringement relate technology action consolidate indiana case august court deny depuy motion summary judgment trial date set september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc receive notice civil claim file nick field supreme court british columbia canada bc civil claim bc civil claim putative class action bring behalf person reside british columbia purchase period september december mcneil infant child overthecounter medicine manufacture fort washington pennsylvania facility bc civil claim allege defendant violate bc business practice consumer protection act canadian statute common law sell medicine allegedly safe andor effective comply canadian good manufacturing practice class certification hearing schedule october adjourn court enter consent order dismissal november conclude action addition april putative class action file johnson johnson johnson johnson sales logistics company llc mcneil ppc inc known johnson johnson consumer inc new jersey superior court camden county behalf person reside state new jersey purchase mcneil overthecounter product december present complaint allege violation new jersey consumer fraud act follow grant motion dismiss filing amend complaint court deny motion dismiss amend complaint discovery underway purport class action file federal court united states district court central district california united states district court southern district illinois johnson johnson johnson johnson consumer companies inc johnson johnson consumer inc jjci allege violation state consumer fraud statute base nondisclosure allege health risk associate talc contain johnson baby powder johnson shower shower product long sell jjci case seek injunctive relief monetary damage include claim personal injury october case transfer united states district court district court new jersey newly create federal multidistrict litigation july court grant johnson johnson jjcis motion dismiss case plaintiff appeal september plaintiff second case voluntarily dismiss complaint august united states customs border protection cbp issue penalty notice janssen ortho llc janssen ortho assess penalty allege improper classification darunavir ethanolate active pharmaceutical ingredient prezista connection importation united states october janssen ortho submit petition relief response penalty notice cbp issue amend penalty notice assess substantial penalty janssen ortho file petition relief july march april putative class action complaint file contact lens patient number court united states johnson johnson vision care inc jjvci contact lens manufacturer distributor retailer allege vertical horizontal conspiracy fix retail price contact lense complaint allege manufacturer reach agreement certain distributor retailer concern price contact lense sold consumer plaintiff seek damage injunctive relief class action case transfer united states district court middle district florida june plaintiff file consolidated class action complaint november june court deny motion dismiss file jjvci defendant discovery ongoing march plaintiff file motion class certification august thirdparty payor file purport class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc orthomcneiljanssen pharmaceuticals inc johnson johnson certain bayer entity allege defendant improperly market promote xarelto safe effective expensive alternative medication fail fully disclose risk complaint seek damage purport class action file united states district court western district washington lifescan inc johnson johnson diabetes test strip manufacturer certain pharmacy benefit manager pbms complaint allege consumer pay inflated price glucose monitor test strip consequence undisclosed rebate incentive pay manufacturer pbms complaint include rico erisa state consumer protection claim complaint seek equitable relief damage november case order transfer united states district court district new jersey lonza sale ag lonza file request arbitration london court international arbitration janssen research development llc janssen lonza allege janssen breach agreement party sublicense certain lonza technology manufacture daratumumab lonzas consent lonza seek monetary damage september strategic product group inc spg file antitrust complaint lifescan inc lifescan scotland ltd collectively lifescan united states district court northern district florida pensacola division spg exclusive distributor unistrip blood glucose meter test strip allege lifescan monopolize attempt monopolize market blood glucose meter test strip compatible certain lifescan meter complaint seek damage september pfizer inc pfizer file antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania pfizer allege janssen violate federal antitrust law contract strategy remicade complaint seek damage injunctive relief november janssen move dismiss complaint begin september multiple purport class action file johnson johnson janssen biotech inc collectively janssen allege janssens remicade contracting strategy violate federal state antitrust consumer law seek damage injunctive relief november case consolidated pretrial purpose united states district court eastern district pennsylvania remicade antitrust litigation october certain united states service member family bring complaint number pharmaceutical medical device company include johnson johnson certain subsidiary allege defendant violate united states antiterrorism act complaint allege defendant provide fund terrorist organization sale practice pursuant pharmaceutical medical device contract iraqi ministry health andover healthcare inc file lanham act case johnson johnson consumer inc april united stated district court district massachusetts andover assert claim natural rubber latex coach sport wrap bandaid brand secureflex wrap bandaid brand hurtfree wrap false andover seek actual damage prejudgment interest thereon disgorgement profit treble damage attorney fee injunctive relief court deny motion dismiss answer file discovery underway february security class action lawsuit file johnson johnson united states district court district new jersey allege johnson johnson violate federal security law failing adequately disclose alleged asbestos contamination body powder contain talc primarily johnson baby powder lawsuit assign district court judge manage personal injury multidistrict litigation johnson johnson subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek cost past andor future remediation restructure company announce restructuring action medical device segment well serve need patient customer todays evolve healthcare marketplace company undertaking action strengthen gotomarket model accelerate pace innovation prioritize key platform geography streamline operation maintain high quality standard company estimate connection plan record pretax restructure relate charge approximately billion billion company record pretax charge million million include cost product sell million include income expense table additional detail total project cost billion record restructuring announce additionally plan company expect restructuring action result position elimination approximately percent medical device segment global workforce month approximately position eliminate receive separation payment restructure announcement company estimate approximately onehalf cumulative pretax cost result cash outlay include approximately million employee severance approximately half cumulative pretax cost noncash relate primarily facility rationalization inventory writeoff intangible asset writeoff follow table summarize severance charge associate spending initiative fiscal year end dollar million severance asset writeoff total restructure charge activity reserve balance january activity reserve balance january current year activity charge cash payment settle non cash accrual adjustment reserve balance december cash outlay severance expect substantially pay month accordance company plan local law include project expense salary employee support initiative consulting expense report independent register public accounting firm shareholder board directors johnson johnson opinions financial statement internal control financial reporting audit accompany consolidated balance sheet johnson johnson subsidiaries december january relate consolidated statement earning comprehensive income equity cash flow year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december january result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso change accounting principle discuss note consolidated financial statement company change manner account present certain element share base payment basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company consolidate financial statement company internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion describe management report internal control financial reporting management exclude abbott medical optics actelion ltd assessment internal control financial reporting december acquire company purchase business combination exclude abbott medical optics actelion ltd audit internal control financial reporting abbott medical optics actelion ltd whollyowne subsidiary total asset total revenue exclude management assessment audit internal control financial reporting represent approximately total asset respectively approximately total revenue respectively relate consolidated financial statement amount year end december definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february serve company auditor determined specific year begin serve auditor company management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal control integrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting company acquire abbott medical optics amo whollyowne subsidiary abbott laboratories actelion ltd consolidated subsidiary actelion february june respectively actelion total asset exclude intangible asset goodwill total revenue represent approximately respectively relate consolidated financial statement period end december amo total asset exclude intangible asset goodwill total revenue represent approximately respectively relate consolidated financial statement period end december acquisition occur fiscal year scope company assessment design effectiveness internal control financial reporting fiscal year exclude mentioned acquisition exclusion accordance sec general guidance assessment recently acquire business omit scope year acquisition base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear alex gorsky dominic j caruso alex gorsky dominic j caruso chairman board directors executive vice president chief financial officer chief executive officer shareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure alex gorsky chairman chief executive officer dominic j caruso executive vice president chief financial officer review participate evaluation base evaluation messr gorsky caruso conclude end period cover report company disclosure control procedure effective report internal control financial reporting information call item incorporate reference management report internal control financial reporting attestation internal control financial reporting include report independent register public accounting firm include item report change internal control financial reporting fiscal quarter end december change companys internal control financial reporting identify connection evaluation require rules exchange act materially affect reasonably likely materially affect company internal control financial reporting company implement multiyear enterprisewide initiative integrate simplify standardize process system human resource information technology procurement supply chain finance function enhancement support growth company financial share service capability standardize financial system initiative response identify deficiency weakness company internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information applicable iii item director executive officer corporate governance information call item incorporate reference discussion audit committee caption item election director board committee material caption item election director stock ownership section compliance section beneficial ownership report compliance proxy statement material caption executive officer registrant report company code business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act code business conduct available company website wwwjnjcomcodeofbusinessconduct copy available shareholder charge write request secretary company principal executive office substantive amendment code business conduct waiver code grant chief executive officer chief financial officer controller post company website wwwinvestorjnjcomgovcfm business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company website wwwinvestorjnjcomgovboardconductcfm copy available shareholder charge write request secretary company principal executive office substantive amendment code waiver code grant member board director executive officer post company website wwwinvestorjnjcomgovcfm business day retain website year item executive compensation information call item incorporate reference material caption item election director director compensation compensation committee report compensation discussion analysis executive compensation table proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent company specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter information call item incorporate reference material caption item stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement item report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan number security issue weighted average number security exercise exercise price remain available outstanding outstanding future issuance equity plan category option right option right compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder longterm incentive plan longterm incentive plan column exclude share reflect column number security issue exercise outstanding option right longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan item certain relationship relate transaction director independence information call item incorporate reference material caption item election director director independence relate person transaction proxy statement item principal accountant fee service information call item incorporate reference material caption item ratification appointment independent register public accounting firm proxy statement iv item